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Functional psychosis is a severe mental illness with often devastating consequences for individuals 
and a high cost to society. One leading aetiopathological hypothesis is the ‘aberrant salience theory’ 
whereby abnormal salience is attributed to stimuli leading to psychotic symptoms mediated by striatal 
dopamine. Reward processing is also thought to be mediated by striatal dopamine and is disrupted in 
psychosis. One aspect of reward processing is motivational salience, whereby perception of an 
incentivising stimulus leads to approach behaviour in an organism. Accumulating data points to a role 
for the endocannabinoid system in both psychosis and reward processing. In particular, the 
phytocannabinoid cannabidiol (CBD) is a promising candidate as a novel antipsychotic. At the core of 
this thesis are two published articles using functional magnetic resonance imaging (fMRI) to 
investigate the neural substrate of motivational salience in health, how it is affected in psychosis and 
the neurocognitive effects of CBD.  
The first article is an international meta-analysis of fifteen original fMRI group maps sourced from 
healthy adult participants (n=346) undertaking the Monetary Incentive Delay Task (MIDT). We 
analysed the anticipation of monetary reward and loss contrasted with the neutral condition. In both 
contrasts there was consistent activation of the striatum and salience network, with more complex 
patterns of activation and deactivation in the central executive network, default network and 
cerebellum. We subsequently compared the anticipation of reward with loss and found significantly 
greater relative deactivation in the left inferior frontal gyrus. 
The second publication reports a randomised double-blind placebo-controlled study using the MIDT 
in which thirty-three participants at clinical high risk for psychosis (CHR) were administered either 
600mg oral CBD or placebo and compared with nineteen healthy controls (HC). CHR subjects represent 
a population of help-seeking individuals who have experienced psychotic-like symptoms or have 
significant genetic risk of developing a psychotic illness, but they remain antipsychotic-naïve. Reward 
and loss anticipation conditions were combined to create a condition of motivational salience, 
subsequently contrasted with neutral. Region-of-interest analysis was confined to two masks 
consisting of striatum/midbrain/hippocampus and the core salience network (anterior 
cingulate/insula). Differences were detected between CHR-placebo and HC groups and CHR-placebo 
and CHR-CBD groups within the core salience network but not within the mask containing the 
striatum. There was increased activation in a region of posterior left insula/parietal operculum in CHR-
placebo compared to HC. Activation in this area in the CHR-placebo group positively correlated with 
psychotic symptoms and negatively correlated with salience perception, as indexed by reaction time 




linked to increased activation in the same region of brain in CHR. Increased activation in the left 
insula/parietal operculum in CHR was attenuated by CBD.  
In conclusion, this thesis establishes that the salience network is activated in motivational salience, 
and that the neurocognitive dysfunction associated with reward processing in psychosis may be based 
in the salience network, in particular insula/operculum regions. Moreover, the effect of CBD in 
attenuating activity in the insula/operculum suggests a potential antipsychotic mechanism-of-action 





















































Psychosis is a severe mental disorder involving the breakdown of evaluation of external reality. There 
are many different diagnostic categories of psychotic disorder, the most well-known being 
schizophrenia, a lifelong disorder characterised by a combination of positive symptoms, such as 
thought disorder, delusions and hallucinations, and negative symptoms, such as avolition, anhedonia 
and blunting of affect. It’s a big problem. The global and lifetime prevalence of primary psychotic 
disorders have been estimated at 0.46% and 0.75% respectively (Moreno-Küstner, Martin et al. 2018), 
the global disability-adjusted life years of schizophreniform disorders at 0.51% (James, Abate et al. 
2018), and the global economic burden can be up to 1.65% of national GDP (Chong, Teoh et al. 2016). 
The incidence of psychotic disorders peaks in the third decade of life. In males, incidence is higher in 
youth, with a steep decline compared to females, for whom there is a smaller secondary peak in the 
fifth decade of life (Kirkbride, Errazuriz et al. 2012, Eranti, MacCabe et al. 2013). Objective recovery 
including clinical and social domains has been estimated from between 14 to 38% (Jääskeläinen, Juola 
et al. 2012, Lally, Ajnakina et al. 2017). Life expectancy is significantly reduced (worse for males) 
(Hjorthøj, Stürup et al. 2017), attributed mainly to vascular disease, cancer and respiratory disease, 
with between five to ten times elevated mortality due to suicide (Das-Munshi, Chang et al. 2017).  
The aetiopathology of schizophreniform disorders remain elusive. There are established associations 
with childhood adversity, such as trauma and abuse, measures of ‘urbanicity’ and ethnicity (such as 
black Caribbean and black African in the UK) (Kirkbride, Errazuriz et al. 2012, Matheson, Shepherd et 
al. 2012). There is a strong genetic component with high estimated heritability, up to 81% in twin 
studies (Sullivan, Kendler et al. 2003). 108 independent genetic loci have been identified through 
genome-wide association study including the dopamine receptor 2 (D2-R) gene, glutamatergic genes 
and genes involved in immunity (Schizophrenia Working Group of the Psychiatric Genomics, Ripke et 
al. 2014), although the presence of such genes confers risk only, being ‘neither necessary nor 
sufficient’ to cause psychosis. The longstanding ‘neurodevelopmental hypothesis’ (Weinberger 1987) 
posits that early insults to the developing brain impact on normal maturation. This is supported by 
evidence of increased risk in low birthweight, obstetric complications, prenatal exposure to viral 
infection and malnutrition (Murray, Bhavsar et al. 2017). Further supporting evidence is now emerging 
for epigenetic effects during pre and post-natal development (Jaffe, Gao et al. 2015). 
Two neurotransmitter systems are at the forefront of aetiological theory and treatment- glutamate 
(Glu) and dopamine (DA) (Howes, McCutcheon et al. 2015). One dominant aetiological theory is the 
‘aberrant salience hypothesis’, whereby hyperdopaminergia in the mesostriatal pathway (from 




(Kapur 2003). Evidence for hyperdopaminergia is robust: all licensed effective antipsychotics block D2-
R, the D2-R affinity of antipsychotics is related to clinical response, antipsychotics have a therapeutic 
index based on D2-R occupancy between 50 to 65%, and presynaptic DA-ergic function is elevated in 
both PET (positron emission tomography) and SPECT (single-photon emission computed tomography) 
studies (Howes, Egerton et al. 2009, Howes, Kambeitz et al. 2012).  
However, in around 20 to 30% of people with schizophrenia, psychotic symptoms do not respond to 
D2-R blockade with conventional antipsychotics. The exact clinical criteria for this ‘treatment-resistant’ 
group are not yet fully codified, though consensus guidelines have been published (Howes, 
McCutcheon et al. 2017). Neuroimaging has identified some differences from treatment-responsive 
groups, including reduced frontotemporal perfusion and grey matter volume, increased white matter 
perfusion, increased basal ganglia perfusion, relatively normal striatal DA synthesis and elevated Glu 
in the anterior cingulate gyrus (ACG) (Demjaha, Murray et al. 2012, Demjaha, Egerton et al. 2014, 
Mouchlianitis, McCutcheon et al. 2016). 
Glu-ergic involvement is predominantly based on the NMDA-R (N-methyl-D-aspartate receptor) 
hypofunction theory, whereby the afore-mentioned leads to disinhibition of GABA-ergic (gamma-
aminobutyric acid) neurons, elevating cortical Glu and leading to excitotoxicity and 
neurodegeneration in key regions of the brain (Olney and Farber 1995, Stone, Morrison et al. 2007). 
There is some evidence for this including genetic studies and the finding of elevated Glu-ergic 
metabolites in the basal ganglia, thalamus and medial temporal lobe (MTL) (Merritt, Egerton et al. 
2016). Yet, to date, there are no effective Glu-ergic antipsychotics.  
The immune system has also been implicated in the pathogenesis of schizophrenia, by genetic studies, 
findings of increased microglia density and expression of pro-inflammatory genes in post-mortem 
studies (van Kesteren, Gremmels et al. 2017), and by elevated cytokines in vivo (Miller, Buckley et al. 
2011). These theories are not mutually exclusive. In fact, immunopathogenesis is linked to NMDA-R 
hypofunction by the finding of NMDA-R autoantibodies in a significant minority of cases of 
schizophreniform disorder (Pollak, McCormack et al. 2013). Moreover, DA and Glu dysfunction are 
linked by the rodent-derived MAM (methylazoxymethanol) model of psychosis, in which MTL 
dysfunction leads to striatal hyperdopaminergia (Modinos, Allen et al. 2015).  
 
Early intervention 
Early intervention in psychosis has clinical roots in the Buckingham Project in the UK (Shanahan, 




the EPPIC (Early Psychosis Prevention and Intervention Centre) program in Melbourne, Australia, 
developed to reduce morbidity in first-episode psychosis (FEP) (McGorry 1993). Early intervention in 
FEP has been found to significantly improve outcomes, including lower relapse, higher remission and 
higher recovery rates, lower treatment discontinuation, lower risk of hospitalisation, reduction of 
symptoms, and improved quality of life and global functioning (Correll, Galling et al. 2018), although 
good outcomes may not be sustained on transfer to standard treatment (Nordentoft, Rasmussen et 
al. 2014). The ‘duration of untreated psychosis’ (DUP) is defined as the time from development of the 
first psychotic symptom to treatment with an antipsychotic. A longer DUP is associated with worse 
prognosis in terms of symptoms, remission, social functioning and global outcome (Penttilä, 
Jääskeläinen et al. 2014). The clinical significance of reducing DUP is now recognised by NHS England 
with the introduction of a 2-week waiting time standard from referral to treatment (Excellence 2016). 
However despite great leaps in clinical service provision, 23% of FEP remain treatment-resistant at 10 
years (84% since illness onset) (Demjaha, Lappin et al. 2017).  
‘An ounce of prevention is worth a pound of cure’ (Henry de Bracton, De Legibus c.1240). One of the 
most robust predictors of poor prognosis is premorbid difficulties (Díaz-Caneja, Pina-Camacho et al. 
2015). The ‘prodrome’ of relatively mild non-specific symptoms and change in general functioning 
prior to the onset of schizophrenia has long been recognised (Docherty, Van Kammen et al. 1978), 
necessitating the codifying of minimum duration and severity of symptoms into the current diagnostic 
classification systems (Keith and Matthews 1991). The first clinical attempt to address the prodrome 
phase started with the opening of the PACE (Personal Assistance and Crisis Evaluation) clinic for young 
people in Melbourne, Australia, in 1994. Three core characteristics were thought to elevate risk for 
developing psychosis in young people, as operationalised in the Comprehensive Assessment of At Risk 
Mental States (CAARMS) (Yung, Yuen et al. 2005): trait-state factors (presence of drop in function and 
first or second degree relative with diagnosed psychotic disorder), subthreshold attenuated psychotic 
symptoms (APS) and brief limited intermittent psychotic symptoms (BLIPS) lasting less than one week 
(Yung, McGorry et al. 1996). Services for people at clinical high-risk (CHR) have since blossomed 
internationally, stimulating research into transition, intervention, the development of further 
diagnostic tools and leading to the controversial inclusion of the Attenuated Psychosis Syndrome in 
the DSM V (Davies, Oliver et al. 2017).  
However, CHR services have been criticised as an ineffective approach to preventing the onset of 
psychosis (van Os and Guloksuz 2017, Ajnakina, David et al. 2018). It is now known that psychotic 
experiences are relatively common in the general population, with prevalence estimated at 7.2% 




may predominantly represent a marker of severity of non-psychotic disorders (van Os and Reininghaus 
2016, van Os and Guloksuz 2017), particularly in adolescence (Kelleher, Keeley et al. 2012). The vast 
majority of CHR subjects do not transition to psychosis and actually have anxiety and/or depression 
(Addington, Piskulic et al. 2017). Initially, there were high rates of transition to psychosis between 30 
to 54% in the first 24 months, but more recently rates appear to have fallen as low as 8 to 17% 
(Ajnakina, David et al. 2018). There are also discrepancies between CHR and FEP populations, for 
example only a fraction of FEP patients in a South London clinic had transferred from the local CHR 
service (Ajnakina, Morgan et al. 2017), males may be under-represented in CHR compared to FEP 
services internationally (Wilson, Patel et al. 2016) and ethnic minorities are under-represented in CHR 
subjects who transition (Valmaggia, Byrne et al. 2018). To date there is no evidence for any effective 
intervention in preventing transition to psychosis (Davies, Cipriani et al. 2018).  
Nonetheless, early intervention in CHR has delivered important aetiological insights, particularly for 
individuals who have transitioned to a psychotic disorder, including: evidence of increased activity in 
the prefrontal cortex, left hippocampus and subcortical structures (Allen, Luigjes et al. 2012), elevated 
hippocampal Glu levels (Bossong, Antoniades et al. 2019), correlation between medial prefrontal 
GABA levels and left hippocampal perfusion (Modinos, Şimşek et al. 2018), progressive increase in 
striatal DA synthesis (Howes, Bose et al. 2011), and progressive grey matter volume loss in the frontal 
cortex (Cannon, Chung et al. 2015). Moreover, CHR research promises new pharmacological 
interventions such as cannabidiol (Bhattacharyya, Wilson et al. 2018) and oxytocin (Davies, Paloyelis 
et al. 2019). 
 
Reward processing and motivational salience in psychosis 
Reward-seeking behaviour is found across the animal kingdom (Barron, Søvik et al. 2010). At its core 
it consists of goal-directed behaviour and adaptive decision-making. It is an iterative learning process, 
whereby perception of an incentivising stimulus induces goal-directed behaviour towards 
consummation of reward. This, in turn, increases the likelihood of the behaviour re-occurring on 
perception of the same stimulus. The intrinsic value or ‘valence’ of an incentive creates salience in an 
organism. Incentives may be innate/intrinsic/primary (such as food) or may be 
learnt/extrinsic/secondary (such as money). The anticipation of a reward following incentive 
presentation creates ‘motivational salience’ and prepares approach behaviour. Motivational salience 




In mammals, the reward mechanism is thought to be mediated by DA-ergic neurons in the striatum 
(Schultz, Dayan et al. 1997) and closely fits an algorithm described by the ‘reward prediction error’ 
(RPE) hypothesis (Schultz 2017). In RPE the difference between the value of the anticipated reward 
and the value of the received reward generates a DA-ergic signal in the striatum which subsequently 
informs future value anticipation. If the same stimulus and reward are presented repeatedly, the DA-
ergic signal propagates earlier in time to the presentation of an incentive, contributing to motivational 
salience.  
Abnormal reward processing is implicated in multiple psychiatric disorders and is at the root of 
addiction psychiatry, whereby an extrinsic chemical (and learnt cues) creates pathological 
motivational salience, aberrant goal-directed behaviour and recurrent consumption of the chemical, 
leading to a three-stage repeating cycle of binge/intoxication, withdrawal/negative affect and 
preoccupation/anticipation mediated by emotional state and executive function (Koob and Volkow 
2016). Abnormal striatal activity and DA-ergic function are consistent findings in animal and human 
studies of substance use disorders (SUD) (Leyton and Vezina 2013). At the same time, aberrant 
salience mediated by striatal DA-ergic neurons is the leading theory of psychotic disorders (Kapur 
2003, Winton-Brown, Fusar-Poli et al. 2014), and fMRI meta-analyses of both SUD and psychotic 
disorders have found abnormal striatal function (Radua, Schmidt et al. 2015, Luijten, Schellekens et 
al. 2017), suggesting there may be a common neural substrate. 
There is epidemiological evidence for a common neural substrate. For decades it been observed that 
people with psychotic mental illness have a high prevalence of SUD (Regier, Farmer et al. 1990, 
Degenhardt and Hall 2001). A recent comprehensive international meta-analysis of 165,811 subjects 
with schizophreniform disorder estimated the prevalence of comorbid SUD (excluding tobacco) at 
41.7%, identifying cannabis (26.2%) and alcohol (24.3%) as the most prevalent substances (Hunt, Large 
et al. 2018). Tobacco use also has long been established as being high in prevalence compared to the 
general population (Mitchell and Dahlgren 1986). SUD prevalence is high in both FEP and CHR with 
rates of cannabis and alcohol use consistently elevated (Cantwell, Brewin et al. 1999, Lambert, Conus 
et al. 2005, Barnett, Werners et al. 2007, Mazzoncini, Donoghue et al. 2010, Wisdom, Manuel et al. 
2011, Addington, Case et al. 2014, Colizzi, Carra et al. 2016, Brunette, Mueser et al. 2018).  
Applied research has demonstrated that reward processing and motivational salience are disrupted in 
psychosis. One behavioural measure of motivational salience is an ‘accelerated motor response’ to 
increasing probability of reward receipt. Using the Cued Reinforcement Reaction Time task, Murray et 
al have demonstrated impairment of this effect in both medicated and unmedicated FEP patients 




using the Salience Attribution Test (SAT), termed ‘implicit adaptive salience’ (Roiser, Stephan et al. 
2008). Using an instrumental learning monetary reward task, Murray et al also reported faster 
reaction time to neutral stimuli in both medicated and unmedicated FEP (Murray, Corlett et al. 2007).  
Observing the SAT with fMRI, Smieskova et al found that reduced implicit adaptive salience was 
associated with clusters of reduced activation in multiple brain regions at whole-brain level in 
unmedicated FEP (straddling left dorsal ACG, left middle frontal gyrus and left precentral gryus), 
medicated FEP (right insula, right ACG, right precentral gyrus, right paracingulate gyrus), and both FEP 
combined (right precentral gyrus/inferior frontal gyrus and right insula) (Smieskova, Roiser et al. 
2015). Furthermore, they reported a negative correlation between hallucination severity and right 
anterior insula activation in unmedicated FEP. Using a variant of the Monetary Incentive Delay Task 
(MIDT), Nielsen et al found that healthy controls improved their accuracy more than unmedicated 
schizophrenia patients following motivationally salient cues, associated with attenuated activation in 
the striatum, ACG, midbrain, thalamus and cerebellum in patients. Furthermore, ventral striatum (VS) 
activation on region-of-interest (ROI) analysis correlated to positive psychotic symptoms (Nielsen, 
Rostrup et al. 2012). After 6 weeks of antipsychotic treatment, ROI-analysis revealed that patients had 
increased activation in the right VS from an attenuated baseline and signal change correlated with 
change in psychotic symptoms (Nielsen, Rostrup et al. 2012). Using the SAT, Schmidt et al found 
reduced ACG-right insula connectivity in adaptive reward prediction in unmedicated FEP correlating 
with unusual thought content on the BPRS (Schmidt, Palaniyappan et al. 2016), an effect not found in 
treated patients. A meta-analysis of monetary reward anticipation in schizophrenia spectrum disorder 
reported bilateral VS hypoactivation and correlation between negative symptoms and the left VS 
(Radua, Schmidt et al. 2015). 
There is also evidence of disrupted motivational salience in CHR. Using the SAT, Roiser et al reported 
increased attribution of reward probability to irrelevant stimuli on visual analogue scale estimation, 
correlating to unusual thought content on CAARMS. On analysing striatal DA synthesis capacity with 
PET, they reported negative correlation between hippocampal activity during irrelevant stimuli in CHR 
and positive correlation in healthy controls (Roiser, Howes et al. 2012). Using the MIDT, Wotruba et 
al found increased activation in reward anticipation in the posterior cingulate, middle frontal gyri and 
superior frontal gyri at the whole-brain level, but no difference in ROI-analysis for VS, right anterior 
insula or medial orbitofrontal cortex (Wotruba, Heekeren et al. 2014). Smieskova et al reported 
relatively less activation in a cluster spanning the right supramarginal gyrus and right inferior parietal 




(Smieskova, Roiser et al. 2015). In the same meta-analysis as above, Radua et al also found bilateral 
VS hypoactivation in CHR (Radua, Schmidt et al. 2015). 
 
The endocannabinoid system, motivational salience and psychosis 
The story of the endocannbinoid system (ECS) starts with cannabis. Cannabis sativa is an ancient 
domesticated crop. There is evidence of its use as a fibre since the Paleolithic era (Adovasio, Soffer et 
al. 1996), and it has been called a ‘camp follower’ of pre-agrarian hunter-gatherer nomadic groups 
(Anderson 1952). Documented medicinal use stems back at least four millennia in China (Abel 1980) 
and Ancient Egypt (Russo 2007), where in particular it is reported that women used it to improve their 
mood (Carod-Artal 2013). Fast-forward to the twenty-first century, and it is still being use as a fibre 
for manufacturing worldwide, but nearly 200 million people now consume it primarily for its 
psychotropic effects (UNODC), attributed to the main psychoactive molecule 9-
tetrahydrocannabinol (9-THC).  
9-THC is not the only chemical unique to the plant. At least 113 phytocannabinoids have now been 
isolated (Aizpurua-Olaizola, Soydaner et al. 2016) since the first molecule (cannabinol) was identified 
at the end of the nineteenth century (Mechoulam, Hanuš et al. 2014). 9-THC itself was first isolated 
in 1964 (Gaoni and Mechoulam 1964). The first cannabinoid receptor (CB1) was cloned in 1990 
(Gerard, Mollereau et al. 1990, Matsuda, Lolait et al. 1990), the first endogenous lipid ligand or 
‘endocannabinoid’ (ECB) arachidonoyl ethanolamide (AEA-‘anandamide’) identified in 1992 (Devane, 
Hanus et al. 1992), the CB2 receptor was cloned in 1993 (Munro, Thomas et al. 1993), and the second 
ECB 2-arachidonoylglycerol (2-AG) was identified in 1995 (Mechoulam, Ben-Shabat et al. 1995). We 
now understand that the ECS is involved in many aspects of physiology, that ECB’s interact with a wide 
range of receptors beyond CB1 and CB2, and a number of ECB-related lipid mediators have been 
identified (Iannotti, Di Marzo et al. 2016). 
In relation to mental illness, the most studied parts of the ECS are CB1, CB2, AEA and 2-AG. CB1 is 
primarily expressed in the central and peripheral nervous system, whereas CB2 is primarily expressed 
on immunocytes (Pertwee 2008). Within the CNS, CB1 is observed throughout the cortex, but it is 
found in high density in the cingulate, frontal, secondary somatosensory and secondary motor cortex. 
It is also found in high density in the hippocampus and amygdala. Density varies in the basal ganglia: 
high in the internal globus pallidus and substantia nigra pars reticulata, moderate in the external 
globus pallidus, caudate and putamen, and low in the VS/nucleus accumbens (NAcc). CB1 is notably 




pathway), but it is present on GABA-ergic projections from the NAcc to the VTA. CB1 is also found in 
high density in the cerebellum on basket cell axon terminals, climbing fibres and parallel fibres 
mediating glutamatergic and GABA-ergic inputs to Purkinje neurons (Hu and Mackie 2015). 
Both CB1 and CB2 are inhibitory G-protein coupled receptors. CB1 is located presynaptically as part of 
a retrograde messenger system (Pertwee 2015). Activation inhibits the release of other 
neurotransmitters such as Glu and GABA from the presynaptic terminal. AEA is a partial agonist at 
CB1, whereas 2-AG is a full agonist at CB1. Both are synthesised on demand and released 
postsynaptically following calcium influx (Di Marzo, Bisogno et al. 2005). AEA is metabolised by fatty 
acid amide hydrolase (FAAH) which is found in dendritic spines on the membranes of mitochondria 
and other organelles (Piomelli 2014). 2-AG is metabolised mainly by monoacylglycerol lipase (MAGL) 
in axon terminals, but also by FAAH (Piomelli 2014). Of note, 2-AG is found in significantly higher 
concentrations than AEA in the rat brain (Stella, Schweitzer et al. 1997) implying a more significant 
role than AEA. 
Evidence of ECS dysfunction in psychosis continues to accumulate. Epidemiologically, cannabis 
consumption is implicated in the both the onset and prognosis of psychotic mental illness. To date, at 
least five independent longitudinal cohort studies have comprehensively demonstrated the 
association between cannabis use and development of psychotic mental illness (Andréasson, Allebeck 
et al. 1987, Arseneault, Cannon et al. 2002, Van Os, Bak et al. 2002, Callaghan, Cunningham et al. 2012, 
Nielsen, Toftdahl et al. 2017). A meta-analysis of 66,186 subjects has confirmed a dose-response 
relationship between level of cannabis use and psychotic outcomes (Marconi, Di Forti et al. 2016). 
Several meta-analyses have identified differences between psychotic disorders associated with 
cannabis use and without, including an earlier onset of psychosis in cannabis users (Large, Sharma et 
al. 2011), higher relapse rates in ongoing cannabis use, longer hospital admissions, more severe 
positive symptoms, worse overall functioning (Schoeler, Monk et al. 2016) and worse adherence to 
medication (Foglia, Schoeler et al. 2017). Schoeler et al reported that continued use of high versus low 
potency (higher 9-THC concentration) cannabis increased risk and frequency of relapse, reduced 
time between relapses and required more intensive care (Schoeler, Petros et al. 2016). Furthermore, 
a recent multicentre case-control study across Europe has estimated that up to 30% of FEP in London 
(50% in Amsterdam) is attributable to high potency cannabis use (Di Forti, Quattrone et al. 2019). 
It is broadly accepted that the molecule responsible for these effects is 9-THC, a partial agonist at 
CB1 (Pertwee 2008). Cannabis potency, as assessed by 9-THC concentration or the 9-THC:CBD ratio, 
is a potentially modifiable risk factor in the aetiology of psychosis. Experimental studies have 




(D'Souza, Perry et al. 2004, Morrison, Zois et al. 2009, Bhattacharyya, Morrison et al. 2010, Colizzi, 
McGuire et al. 2018). Psychotic symptoms in cannabis users have been linked to polymorphisms of 
the AKT1 and COMT genes (Caspi, Moffitt et al. 2005, Morgan, Freeman et al. 2016). Independent of 
psychosis and as a stand-alone SUD in its own right, cannabis use can lead to a dependence syndrome 
(Budney, Roffman et al. 2007, Hall and Degenhardt 2007) with a recognised withdrawal (Budney, 
Hughes et al. 2004), development of tolerance (Colizzi and Bhattacharyya 2018), evidence of harm 
(Moore, Augustson et al. 2005, Fergusson and Boden 2008) and disruption of Glu metabolism (Colizzi, 
McGuire et al. 2016). Yet despite growing medical concern, there has been a trend toward increasing 
concentrations of 9-THC in cannabis over the last few decades (Mehmedic, Chandra et al. 2010, 
Cascini, Aiello et al. 2012, ElSohly, Mehmedic et al. 2016, Dujourdy and Besacier 2017), prompting calls 
for global monitoring (Freeman and Swift 2016).  
Aside from the effects of exogenous 9-THC, internal ECS abnormalities are also associated with 
psychosis. AEA has been shown to be elevated in the cerebrospinal fluid (CSF) of antipsychotic-naïve 
patients with schizophrenia (Leweke, Giuffrida et al. 1999), a finding repeated more than once and 
inversely correlated with psychotic symptoms (Giuffrida, Leweke et al. 2004, Leweke, Giuffrida et al. 
2007). AEA is also elevated in prodromal subjects, where, counterintuitively, lower levels predict a 
higher transition risk (Koethe, Giuffrida et al. 2009). AEA is in fact low in otherwise-healthy cannabis 
users, and levels correlate negatively with psychotic-like symptoms on abstinence (Morgan, Page et 
al. 2018). Additionally, PET has shown that CB1 binding and availability are altered in schizophrenia 
both cortically and subcortically (Ceccarini, De Hert et al. 2013, Ranganathan, Cortes-Briones et al. 
2016). 
The ECS is also involved in reward processing, including motivation for primary rewards such as food 
and sex (Laredo, Marrs et al. 2017), and also in SUD (Manzanares, Cabañero et al. 2018). Thus far, 
genetic studies are inconclusive for the role of the CB1 gene (CNR1) in psychosis (Gouvêa, Santos Filho 
et al. 2017), but polymorphisms of both CNR1 and the FAAH gene have been associated with SUD 
(López-Moreno, Echeverry-Alzate et al. 2011). CB1 is found in key areas associated with reward 
including the GABA-ergic projections from the NAcc to the VTA as already mentioned, and DA 
signalling may be mediated by presynaptic CB1 on GABA-ergic terminals in the VTA (Mátyás, Urbán et 
al. 2008, Melis, Muntoni et al. 2012). 
Rodent studies have suggested a direct role of the ECS in motivational salience. In an operant 
sensation seeking task, CNR1-knockout mice engaged in goal-directed behaviour less than wild-type 
mice, and FAAH-knockout mice engaged in more (Helfand, Olsen et al. 2017). CB1 agonism by AEA and 




agonism by 2-AG in the VTA increases cue-evoked DA release in the NAcc and goal-directed behaviour 
(Oleson, Beckert et al. 2012). CB1 agonism with 2-AG and noladin changes appetite for specific dietary 
components in free-feeding rats (Deshmukh and Sharma 2012). The administration of the CB1 agonist 
‘WIN’ prior to conditioning enhanced approach behaviour to a conditioned stimulus (Brancato, 
Cavallaro et al. 2018). Administration of AEA optimises effort:reward decisions in a free-choice food 
processing task (Zona, Fry et al. 2017). In the inherited neurodegenerative condition Huntington’s 
Disease (HD), there is characteristic degeneration of striatal medium spiny neurons (GABA-ergic 
inhibitory cells, comprising 95% of neurons in the striatum) associated with apathy. In the HD mouse-
model, behavioural deficits are present in higher effort:reward choices, but the MAGL inhibitor JZL-
184 has been shown to restore motivation to overcome higher cost rewards by elevating 2-AG [105]. 
In contrast, CB1 antagonism with rimonabant reduces cue-evoked dopamine release in the NAcc and 
goal-directed behaviour (Oleson, Beckert et al. 2012), and also inhibits cue-induced reinstatement of 
learned goal-directed behaviour (Hernandez and Cheer 2011).  
In humans, behavioural and neuroimaging studies have implicated the ECS in reward processing, 
salience and motivational salience. Acute 9-THC challenge impairs salience processing in non-
psychotic subjects (Bhattacharyya, Crippa et al. 2012). In healthy controls, 9-THC administration 
reduces the likelihood of high effort choices in the ‘Effort Expenditure for Rewards Task’ (Lawn, 
Freeman et al. 2016). In healthy subjects, 9-THC induces DA release in the striatum (Bossong, Mehta 
et al. 2015) and has been shown to attenuate activation of bilateral inferior temporal gyrus and left 
inferior parietal cortex during reward feedback in the MIDT (van Hell, Jager et al. 2012). Using the 
novel method of presenting visual followed by gustatory stimuli of rewarding (sight and taste of 
chocolate) and aversive (sight and taste of unpalatable strawberries) food, rimonabant has been 
shown to attenuate activation in the right orbitofrontal cortex during anticipation of reward and in 
right VS/putamen during consummation of an aversive stimulus (Horder, Harmer et al. 2010). 
Regarding chronic cannabis users, motivational salience is enhanced behaviourally in response to 
cannabis cues (Wijayendran, O’Neill et al. 2016). Using the MIDT with fMRI, there are multiple regions 
of attenuation including bilateral NAcc, caudate and left putamen, and enhanced activation in bilateral 
middle temporal gyri, right cuneus and parahippocampal gyrus (van Hell, Vink et al. 2010). On PET 
scanning, Bloomfield et al reported reduced DA synthesis capacity in the striatum (Bloomfield, Morgan 
et al. 2014), correlating with diminished goal-directed behaviour (Bloomfield, Morgan et al. 2014). 
Using the SAT, Bloomfield et al reported a positive correlation between psychotic-like symptoms and 




dependence and implicit aberrant salience, and a loss of correlation between implicit aberrant 
salience and striatal DA synthesis capacity (Bloomfield, Mouchlianitis et al. 2016). 
 
Cannabidiol 
Intriguingly the cannabis plant appears to be a ‘pharmakon’, offering both poison and cure. The 
antipsychotic effect of the phytocannabinoid cannabidiol (CBD) was first reported in the case study of 
a 19 year-old female with schizophrenia (Zuardi, Morais et al. 1995). In regular cannabis users, there 
is evidence that CBD content in cannabis reduces the psychotic-like symptoms induced by higher levels 
of 9-THC (Morgan and Curran 2008). In healthy subjects, CBD administration curbs the 
psychotomimetic effects of 9-THC (Bhattacharyya, Morrison et al. 2010, Englund, Morrison et al. 
2013). There is now clinical evidence of the potential efficacy of CBD as a novel antipsychotic agent in 
psychotic mental illness (Leweke, Piomelli et al. 2012, McGuire, Robson et al. 2018), and it may 
normalise MTL, midbrain and striatal dysfunction in CHR subjects (Bhattacharyya, Wilson et al. 2018).  
Oral administration of CBD is subject to significant first-pass effect with bioavailability estimated 
between 13 to 19% (Scuderi, Filippis et al. 2009). The time to maximum plasma concentration of oral 
CBD is around four to five hours after administration, and there is a large volume of distribution (high 
tissue distribution) (Taylor, Gidal et al. 2018). It is protein-bound, highly lipophilic and readily crosses 
the blood brain barrier with rapid distribution to the brain and adipose tissue (Gaston and Friedman 
2017). CBD is subject to hepatic metabolism, mainly by CYP (cytochrome P450) enzymes 3A4 and 2C19 
(Jiang, Yamaori et al. 2011). It is also an inhibitor of CYP enzymes, including its own major metabolisers 
2C19 and 3A4 (Zendulka, Dovrtelová et al. 2016). The main circulating metabolites have been reported 
as follows: 7-carboxy-CBD, CBD, 7-hydroxy-CBD, 6-hydroxy-CBD (Taylor, Gidal et al. 2018). In a study 
of repeated oral administration in healthy subjects, steady state was achieved after 2 days. Elimination 
was multiphasic, with effective elimination half-life (of the dose) between 10 to 17 hours and terminal 
elimination half-life of steady-state plasma concentration around 60 hours (Taylor, Gidal et al. 2018). 
Excretion of metabolites is mostly through faeces, though a small proportion is via urine (Gaston and 
Friedman 2017). 
Remarkably, CBD has low affinity at CB1 and CB2 and is active at many alternative sites, including 
other metabotropic receptors and ion channels within the emerging ECS, adenosine A2A, serotonin 5-
HT1A, -adrenoceptors, D2-R,, GABAA, and -opioid receptors (McPartland, Duncan et al. 2015). 
Accordingly, there are a number of different potential mechanisms of action, for example 




or by encouraging synthesis of AEA and 2-AG by stimulating arachidonic acid release (McPartland, 
Duncan et al. 2015). Specifically concerning activity at CB1, it has recently been reported to act as a 
negative allosteric modulator (Laprairie, Bagher et al. 2015, Tham, Yilmaz et al. 2018). 
The relationship between CBD and 9-THC is complex. CBD may potentiate the effects of 9-THC as 
well as acting as a functional antagonist (McPartland, Duncan et al. 2015). There is evidence of an 
augmentation of psychoactive effects and alteration of 9-THC pharmacokinetics in one animal study 
(Klein, Karanges et al. 2011). However, CBD has a favourable safety profile; the most common side 
effects are tiredness, diarrhoea and appetite changes, although there is a lack data for chronic 
administration (Iffland and Grotenhermen 2017).  
 
Thesis rationale 
What is the neural substrate of motivational salience in humans in health? Is there a relationship 
between altered motivational salience in psychosis and psychopathology? How are differences in 
motivational salience in psychosis affected by CBD? What is the neurocognitive mechanism of the 
putative antipsychotic effect of CBD? The main aim of this MD(res) is to investigate abnormalities in 
motivational salience in psychosis and the neurocognitive effects of cannabidiol, detected by fMRI.  
In order to meaningfully interpret any reward processing differences in psychosis, it is crucial to have 
some understanding of normal functioning in health. The MIDT was designed to capture brain function 
during reward processing. It is well established and confers the advantages of adaptability and 
flexibility, breaking down processing into discrete stages of anticipation and feedback. The 
anticipation stage represents a form of motivational salience. In order to determine the neural 
substrate of motivational salience, we conducted the first ever meta-analysis of original group map 
data of the anticipation phase of the MIDT. 
The clinical high-risk state offers access to the neural substrate of psychosis, without modification by 
antipsychotic medication and without severe loss of evaluation of reality. Given the evidence of 
disrupted motivational salience in CHR and guided by findings from the meta-analysis of motivational 
salience in health, we investigated differences in motivational salience between CHR subjects and 
matched healthy controls using the MIDT. The endocannabinoid system is involved in psychosis and 
motivational salience, and cannabidiol promises a potentially ground-breaking non-DA-ergic form of 
treatment. We therefore subsequently investigated the acute effect of CBD on motivational salience 




























This thesis involved the application of functional magnetic resonance imaging (fMRI) to index the 
neurophysiological response of brain regions during the processing of rewarding stimuli. The 
methodologies of the two constituent publications are contained within each articles and respective 
supplementary materials. The core methodologies and techniques are evaluated in this chapter, but 
first the principles of fMRI and the chosen reward processing task are explained below. 
 
Imaging activity in the brain: functional magnetic resonance imaging (fMRI) 
Magnetic resonance imaging is a technique of producing non-invasive images of tissue inside the body. 
It involves the creation of a powerful magnetic field, the ‘B0’ field, by an MRI scanner typically between 
1.5 to 7 Tesla in strength. In nature, protons, such as the nucleus of the hydrogen atom, spin 
generating their own magnetic field. The axis of spin also rotates and is known as ‘precession’ creating 
a local net magnetic field. An MRI scanner applies a magnetic field aligning proton spin (both parallel 
and antiparallel to the field), creating net magnetisation in the same direction as the field. A radio 
frequency (RF) pulse is then emitted. The frequency of this pulse is known as the ‘Larmor frequency’ 
and is the precise frequency to change a proton’s energy state in a given magnetic field by resonating 
at the same frequency as precession. This causes phase alignment of precession and ‘spin-flip’ 
whereby the number of antiparallel magnetic moments equals parallel and the net magnetic vector 
shifts to 90 degrees from the spin axis. The protons then release this energy in the form of ‘T1’ or 
‘spin-lattice’ relaxation, losing spin-flip and emitting a radio frequency signal detected by a receiver 
coil in the MRI scanner. The rate of T1 relaxation differs between tissues, being faster in fat than in 
water. This signal decays more quickly than expected from this process alone because of ‘dephasing’ 
of protons, known as ‘T2’ or ‘spin-spin’ relaxation. Most of the protons generating this signal are 
contained in water molecules. Bodily tissues contain many tiny regional differences in magnetic field 
which enhance dephasing. The combined decay of all dephasing is known as ‘T2* relaxation’ 
(McRobbie, Moore et al. 2003, Kempton 2006, Vink, van den Heuvel et al. 2007).  
To create 3-dimensional images, additional magnetic field gradients are superimposed on the main B0 
field across the brain so that different regions precess at different frequencies and phases depending 
on their spatial location. The brain is divided into planes or ‘slices’ whereby a narrow range RF pulse 
is emitted which affects protons in a narrow range of magnetic field strength. This ‘slice excitation 
pulse’ initiates a spin-flip in protons in that slice without affecting other slices. Within this 2D plane, a 
‘phase encoding’ magnetic field gradient is applied in one direction, e.g. posterior-anterior, then 




encoding’ magnetic field gradient is then applied orthogonally across the remaining dimension, e.g. 
left-right, such that there is different resonant frequency depending on location (McRobbie, Moore et 
al. 2006). The signal detected by the coil from each step in the sequence contains both phase and 
frequency spatial information, building an image in ‘k-space’. In turn the k-space image can be 
decomposed into the constituent frequencies and amplitudes by Fourier transformation into a 2D 
image of the slice (McRobbie, Moore et al. 2003, Kempton 2006, Vink, van den Heuvel et al. 2007). 
MRI is not without drawbacks. There are significant problems with artefact in MRI. For example, 
magnetic susceptibility varies between tissues, and boundaries can generate local magnetic field 
gradients. Most striking are air-tissue boundaries such as sinuses near the brain which render regions 
including the lateral temporal lobe and orbitofrontal cortex sensitive to signal distortion. Head 
movement by the subject in the scanner can also lead to misleading changes in signal intensity. 
 
The BOLD signal 
As neurons generate action potentials and synaptic transmission, so metabolic demand increases and 
more oxygen is required. Local vasodilation is triggered increasing oxygenated blood flow to the area, 
in excess of need. This is called the haemodynamic response. Functional MRI is based on the ground-
breaking discovery that the T2 relaxation signal in blood vessels and perfused brain tissue decreases 
with deoxygenation of haemoglobin (Ogawa, Lee et al. 1990). Because oxygenated blood exerts a 
weaker effect on surrounding magnetic field than ‘paramagnetic’ deoxygenated blood, it exhibits 
slightly more stability in the local magnetic field and prolonged T2* relaxation. This is known as the 
blood oxygenation level-dependent (BOLD) signal. The BOLD signal peaks at about 5 to 6 seconds, 
representing around 1 to 5% increase in intensity of signal of the area, returning to zero after about 
20 seconds. This signal allows in vivo study of physiological activity in the brain (McRobbie, Moore et 
al. 2003, Kempton 2006, Vink, van den Heuvel et al. 2007).  
The physiological mechanism underlying the BOLD signal is generally assumed to be related to 
synaptic activity (Attwell and Iadecola 2002), but understanding is far from comprehensive. The 
relationship between neuronal activity and change in blood flow is known as ‘neurovascular coupling’, 
and a number of cellular mechanisms have been proposed, for example that increasing local 
glutamate stimulates metabotropic glutamate receptors on astrocytes ultimately leading to local 
prostaglandin release and local vasodilation, or that cortical interneurons release of vasoactive 




fMRI relies on contrasting the BOLD signal from two physiological states in the brain known as the 
‘subtraction paradigm’. This could be the difference between two related conditions induced by a 
cognitive task thought to involve a similar set of cognitive processes, and the difference in signal 
represents one or more cognitive processes of interest. This is based on assumption that cognitive 
processes can simply be added or subtracted, known as ‘cognitive subtraction’ (Harrison and Pantelis 
2010). 
 
Analysing images: Statistical Parametric Mapping (SPM) 
SPM (https://www.fil.ion.ucl.ac.uk/spm/) is a freely available software package providing a 
framework for the analysis of neuroimaging data (Penny, Friston et al. 2007). It was originally created 
by Karl Friston in 1991 and developed by co-authors associated with the Wellcome Trust Centre for 
Neuroimaging. It is comprised of three main processes: spatial transformation of data known as 
‘preprocessing’, the application of the parametric general linear model (GLM) to each voxel to describe 




In order to study a group of subjects, fMRI data must be preprocessed. Initially, this is broken down 
into four discrete stages: realignment, coregistration, normalisation and smoothing. All subjects will 
naturally move their head during an MRI scan described by six parameters- three ‘translations’ (up-
down, left-right, forward-backward) and three ‘rotations’ (x/y/z axes). All functional images are re-
aligned to the first functional image by rigid body transformation. This involves determination of the 
specific parameters needed for each image to be realigned, then resampling and interpolation of the 
data to obtain new values. The realigned functional images are then coregistered (realigned again) 
with the structural T1 image, so that the BOLD signal is superimposed on the correct anatomical 
location. Because no two brains are exactly the same, the images must then be normalised to a 
standard template, such as MNI space (Montreal Neurological Institute). In this process, the 
differences between the template and original brain are minimalised by adjusting in twelve 
parameters: translation (3), rotation (3), scaling and skewing on the x/y/z axis. Finally, the images are 
intentionally blurred, known as ‘smoothing’, in which data is convolved with a Gaussian kernel 
described by the term ‘full width at half maximum’ (FWHM; width in mm at 50% of the peak value). 




reducing the signal:noise ratio and increasing overlap between subjects, of benefit in group analysis 
and increasing statistical validity (Kempton 2006, Vink, van den Heuvel et al. 2007). 
Finally, data is subject to slice-time correction. The brain is scanned continuously during fMRI, and 
each whole-brain volume contains approximately 30 slices in a specific temporal order. The time 
elapsed from the start of a whole-brain scan to the end is known as the ‘repetition time’ (TR), which 
could be up to 3000ms. However, during analysis it is assumed that all slices are from the same time-
point. Considering the duration of the BOLD response is only 5 to 6 seconds, a 3 second difference 
between the first and last slice is considerable. To correct for this, slices are shifted in time to a 
reference time point by interpolation of data collected before and after the reference time-point.   
 
Modelling and the general linear model (GLM) 
Experimental tasks designed for fMRI are traditionally categorised as ‘block design’ or ‘event related’. 
In a block design, task conditions are maintained for an extended period of time to stimulate robust 
cognitive engagement resulting in a relatively large BOLD signal. For an event related design, 
conditions are shorter and more discrete allowing randomisation of timing and order. During an 
experimental task, a whole-brain scan is performed every few seconds (TR) creating a ‘timeseries’ of 
data points at each voxel. In a typical fMRI scan, there may be around 100,000 to 200,000 voxels. A 
‘brain mask’ must be created which excludes voxels below a specific signal intensity, i.e. voxels outside 
the brain. The BOLD signal is modelled by the ‘haemodynamic response function’ curve (see Lindquist 
et al for further discussion (Lindquist, Meng Loh et al. 2009)), which is convolved with experimental 
parameters to create predictor variables. Of note the BOLD series varies within and between 
individuals, for example in duration and onset.  
The signal detected from an individual voxel naturally varies over time and consists of the sum of 
effects of interest, effects of no interest and random error. Effects of interest refers to signal variation 
induced by the task. Effects of no interest are known sources of error such as drift of the magnetic 
field over time, physiological noise (e.g. head movement, breathing) and low frequency noise due to 
heating. The GLM assumes a linear relationship between a predictor variable and the signal, whereby 
y (=signal) = xb (x=predictor variable, b = ‘b-value’/parameter estimate/beta/effect size) + e (=error) 
Predictor variables are the variables defined by experimental design and potential confounds, and 
they are expressed in the design matrix. The b-value is an estimated multiplication scalar or ‘regression 




It is calculated for each voxel by finding the weighted predictor variable that best fits the observed 
data by yielding the smallest residual error using the ordinary least squares method. The residual error 
is the part of the signal not explained by the model, known as the residual mean square. The final 
model xb is actually the combined contribution of all weighted predictor variables. Activation due to 
the model (i.e. the combined relative contribution of predictor variables) is expressed in the form of 
a t-value which depends on the b-value and the ratio of explained versus unexplained variance in 
signal data: t = b* √(explained variance due to model/unexplained variance). 
Explained variance is signal variability described by the prediction model, whereas unexplained 
variance is created from the observed timeseries data minus the model prediction, known as the 
residuals. If more variance can be explained, there is less unexplained variance, and the t-value 
increases. In SPM, unexplained variance is depicted as the residual mean square error image. 
 
Statistical inference 
The b-value determined by the GLM can be used for statistical inference by testing the null hypothesis 
that either a linear combination of b-values is zero (t-test) or that all the b-values are zero (f-test). The 
former is calculated by means of subtraction of one b-value from another creating a contrast. The 
corresponding weighted vector is known as the contrast vector. A ‘t-value’ or ‘t-statistic’ is then 
calculated by dividing the contrast vector by the standard error of the contrast, estimated with the 
residual mean square error of the entire model. All t-values are combined in the ‘SPM(t)’ file with the 
coordinates of each corresponding voxel to produce a 3D image. The traditional p-value for each voxel 
can then be calculated using a one-sample t-test.  
However, given the thousands of individual voxels being tested, the threshold for individual 
significance must be raised to maintain the probability of type 1 error at the standard 5% for the 
whole-brain image, known as ‘family-wise error correction’. One such method is the traditional 
Bonferroni correction, whereby each p-value is divided by the number of tests (voxels). However, this 
is based on an incorrect assumption that all observations are independent. Random Field Theory (RFT) 
is a correction technique based on volume and smoothness which is more sensitive and less 
conservative. Briefly in RFT, voxel sizes are discounted and search volume expressed in terms of 
smoothness or ‘resels’ (resolution elements) consisting of a number of voxels falling within the FWHM. 
The final statistical parametric map (SPM) is thresholded by height (t-value) and spatial extent, yielding 
three groups of inferences: set-level (number of clusters exceeding height and volume thresholds), 




local maxima). When testing a single group of subjects, p-values are calculated by standard one-
sample t-test. The two-sample t-test is used to compare two groups. 
 
Capturing reward processing with fMRI: the monetary incentive delay task 
The monetary incentive delay task (MIDT) was developed by Brian Knutson and colleagues in the 
1990’s to capture the neural substrate of reward processing. Money was chosen as an incentive, 
because it is a more universal and consistent incentive stimulus than other forms such as imagery, 
taste or sound (Knutson and Heinz 2015). In essence, the MIDT is a time-dependent visuo-motor task 
involving rapid incentivised response to a learned visual cue. It involves presentation of a sequence of 
three visual stimuli- a cue indicating monetary value, a target indicating that the subject should press 
a button on time, and visual feedback informing the participant of success, failure and winnings. When 
combined with fMRI, t-maps of activity can be created for the anticipation of reward/punishment, 
feedback of success/failure and associated ‘neutral’ conditions where the monetary value is zero. Each 
of these can be subsequently contrasted to gain insight into the different patterns of activation. It is 
well-suited to practical experimental manipulation, allowing modification of valence magnitude and 
distinction between the behaviourist concepts of reward and punishment through delivery or 
deduction of reward. The MIDT (and modified variants) is capable of capturing multiple aspects of 
reward processing including initial presentation of an incentive, approach/avoidance behaviour, 
reward learning, delayed reward discounting (Lutz and Widmer 2014) and even reward prediction 
error (Abler, Walter et al. 2006). 
The MIDT has now been used to investigate underlying pathology of numerous psychiatric disorders, 
contributing data to several major meta-analyses in addiction (Luijten, Schellekens et al. 2017), major 
depression (Zhang, Chang et al. 2013), bipolar disorder (Chen, Suckling et al. 2011), psychosis (Radua, 
Schmidt et al. 2015) and ADHD (Plichta and Scheres 2014). It has been used in psychoactive drug 
challenge studies (van Hell, Jager et al. 2012) and to investigate mechanisms of action of therapeutic 
interventions including nicotine replacement therapy (Rose, Ross et al. 2013), methylphenidate (Stoy, 
Schlagenhauf et al. 2011), antidepressants (Ossewaarde, Verkes et al. 2011, Stoy, Schlagenhauf et al. 
2012) and antipsychotics (Nielsen, Rostrup et al. 2012). 
However, it is important to remember that MIDT is not designed to capture primary intrinsic rewards. 
While there appears to be substantial overlap, differences in regional brain activation particularly in 




involving intrinsic rewards such as food and sex, with the former engaging the orbitofrontal cortex 
and the latter the anterior insula (Sescousse, Caldú et al. 2013). 
 
Publication 1. The neural substrate of reward anticipation in health: a meta-analysis of 
fMRI findings in the monetary incentive delay task 
Fundamentally, understanding the aetiology of a disorder requires a robust model of healthy structure 
and function. Therefore, to determine how CHR subjects may deviate from health and whether CBD 
has any measurable effect, we first needed to describe the brain regions normally engaged during the 
anticipation of rewarding stimuli. 
The original investigations of the MIDT were conducted in healthy adults (Knutson, Westdorp et al. 
2000, Knutson, Adams et al. 2001) and found that anticipation of reward (versus neutral) was 
associated with activation of multiple regions already implicated in reward prediction (bilateral 
nucleus accumbens, bilateral caudate and left putamen). Later meta-analyses have been conducted 
looking at reward anticipation in healthy adults using a variety of cognitive tasks and a mixture of 
different incentives, such as monetary, food, points, social feedback and pleasing images (Liu, Hairston 
et al. 2011, Diekhof, Kaps et al. 2012, Bartra, McGuire et al. 2013). At the time of writing, there have 
been three published meta-analyses of the MIDT in healthy adults aside from ours. The first (Knutson 
and Greer 2008) contrasted anticipation win directly with anticipation lose, the second (Oldham, 
Murawski et al. 2018) contrasted both win and lose with neutral conditions, and the third (Dugré, 
Dumais et al. 2018) focused on loss anticipation and outcome contrasted to neutral. All found that 
regions implicated in reward prediction and the salience network were activated in anticipation.  
Our study advances on the methodology of all three previous meta-analyses, because of the exclusive 
use of original unthresholded whole-brain group t-maps with the meta-analytic software SDM (Seed-
based d Mapping, previously ‘Signed Differential Mapping’) (Radua and Mataix-Cols 2009, Radua, Van 
Den Heuvel et al. 2010, Radua and Mataix-Cols 2012, Radua, Mataix-Cols et al. 2012, Radua, Rubia et 
al. 2014). The data used by the afore-mentioned meta-analyses consisted of the coordinates and t-
values of thresholded peaks extracted from published studies. Both Knutson et al and Oldham et al 
used the well-established activation likelihood estimation (ALE) technique (Turkeltaub, Eden et al. 
2002). Dugre et al used the SDM software to analyse coordinate data. ALE and other peak probability 
methods calculate the regional frequency of reported peaks and assume equal activation. Purely 
coordinate-based meta-analyses (CBMA) do not fully account for within and between-study variation, 




al. 2018). It has been shown that there is a poor similarity between CBMA and image-based meta-
analysis (Salimi-Khorshidi, Smith et al. 2009). For CBMA, SDM offers significant benefits over ALE by 
attempting to recreate original group maps from the available data, including both hyper and 
hypoactivations (hence ‘signed differential’), and assigning each voxel an effect size. Consequently, 
both published coordinate and original group map data can be combined. While the results of ALE-
based meta-analysis may be interpreted as indicating the spatial convergence of previous findings, 
SDM-based can be interpreted as direct increase or decrease in activity in the brain (Müller, Cieslik et 
al. 2018).  
The basic computation in SDM is the calculation of mean voxel value from the means for each study 
weighted by the inverse of the variance. This is subsequently thresholded by cluster size and local peak 
z-score. However, the software also includes additional statistical analyses, including between-group 
comparison, ‘Jacknife’ sensitivity, inter-study heterogeneity, and publication bias by funnel plot and 
Egger’s test. Jacknife sensitivity, also known as ‘leave-one-out’ analysis, involves repeating the mean 
analysis multiple times, leaving out a single map each time. If the same region is found to be significant 
in most of the mean maps, then the finding is replicable. In order to simplify visual map interpretation, 
we created a density map of all Jacknife maps to easily inspect for areas differing in replicability as 
used by Luijten et al (Luijten, Schellekens et al. 2017). Inter-study heterogeneity is calculated from the 
sum of square differences between individual studies and the overall group, creating ‘QH maps’ which 
are be thresholded for significance. Again, to simplify interpretation we created density maps of 
thresholded significant heterogeneity for visual inspection. Funnel plots are a visual technique for 
assessing publication bias, with effect-size on the x-axis and precision (indexed by standard error in 
this case) on the y-axis. An unbiased plot should resemble an inverted funnel, with smaller studies 
scattered at the bottom and larger studies narrowing at the top. If the plot appears asymmetrical, this 
demonstrates bias. Egger’s test investigates funnel plot asymmetry using a test for Y intercept = 0 in 
linear regression of precision (1/standard error) on the x-axis and standardised effects size (effect 
size/standard error) on the y-axis. 
In 2014, we conducted a systematic literature search of 4 databases (EMBASE, MEDLINE, PsychINFO 
and CINAHL) using online software published by NICE (https://hdas.nice.org.uk/) for titles and 
abstracts containing the text ‘monetary’, ‘reward’, ‘incentive’, ‘anticipation’ and/or ‘fMRI’ plus 
variants, complemented by a full text search of PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) 
using the same words. After screening articles for relevance, we contacted each study group offering 
collaboration and requesting available healthy adult group map data. Maps received were then further 




of-view restrictions before inclusion in the analysis. Published coordinate-only data were additionally 
extracted from the remaining articles and combined with original group maps using SDM. 
Following preliminary analysis, further methodological refinement was required. Firstly, the combined 
data results demonstrated significant publication bias. This was controlled by simply excluding the 
coordinate-only data leaving pure group map data. Secondly, the sheer scale of significant findings 
was overwhelming with hundreds of peaks and clusters exceeding 1000 voxels. Initially we sought to 
use the simple false discovery rate correction (p-values reported in the paper), but this was not robust 
enough. Crossing scientific disciplines, we identified a solution from particle physics known as the ‘5-
sigma’ threshold (z-score>5, p<0.0000003), a concept whose equivalent has been called for in 
medicine (Horton 2015). Finally, we used an atlas of the human brain to accurately identify the 
anatomical location of peaks (Mai, Paxinos et al. 2007). 
 
Publication 2. Cannabidiol attenuates insular dysfunction during motivational salience 
processing in subjects at clinical high risk for psychosis 
Population sample 
The second study of this thesis was an experimental design, investigating reward processing in 
psychosis, specifically differences in motivational salience induced by the MIDT between subjects at 
clinical-high risk (CHR) for psychosis and healthy controls and the acute effect of cannabidiol on 
motivational salience in CHR subjects.  
Once psychosis is diagnosed, most individuals will receive treatment with antipsychotic medication, 
who’s common pharmacodynamic action is D2-R antagonism. Antipsychotic treatment is associated 
with structural brain changes (Vita, De Peri et al. 2015). Studying CHR subjects at risk of developing 
psychosis confers the advantage of antipsychotic naivety and low risk of possible neurogenerative 
change, offering ‘cleaner’ insights into the underlying aetiology. In addition, DA-ergic activity is central 
to reward processing models, and the CHR sample offers insight into an unmodified DA-ergic system 
and the effect of a cannabidiol challenge on motivational salience. 
However, the CHR state is not a definitive precursor to psychosis. CHR samples have been criticised 
for not being representative of first-episode psychosis populations (FEP). There are high rates of false 
positives, falling transition rates, and differing demographics (Ajnakina, David et al. 2018) including 
under-representation of males (Wilson, Patel et al. 2016). In one cohort from South London, only 4.1% 
of FEP had had any contact with the well-established partner CHR services (Ajnakina, Morgan et al. 




transition (van Os and Guloksuz 2017). Given that the prevalence of subclinical psychotic symptoms 
has been estimated at 5% in the general population (van Os, Linscott et al. 2009), it has been proposed 
that attenuated psychotic symptoms are a more sensitive marker for severity of non-psychotic states 
(van Os and Guloksuz 2017) rather than transition to psychosis and could represent a pluripotent risk 
syndrome for a range of mental disorders (Yung, Woods et al. 2012). 
The aim of the second experimental study was two-fold: first, to determine differences in brain 
activation between CHR subjects and a sample matched healthy controls, and secondly to investigate 
whether CBD has any detectable effect on function on identified areas of difference. The first study of 
this thesis produced comprehensive whole-brain maps of increased and decreased activation in 
reward anticipation, confirming the involvement of the striatum and salience network in motivational 
salience. Indeed, the resultant maps have the potential to be used as data-based region-of-interest 
(ROI) masks (as opposed to hypothesis-driven) for future research. However, because of the relatively 
small sample sizes for the experimental study, we instead chose hypothesis-driven ROI’s of the core 
salience network (anterior cingulate gyrus and insula) and mesostriatal-medial temporal lobe. 
Design 
The second study was drawn from a larger project, a 3-week randomised placebo-controlled double-
blind, parallel-arm pharmacological challenge and fMRI investigation of the potential of CBD as an 
intervention in CHR subjects. Because of the parallel arm design, the acute single dose effect of CBD 
could not be repeated within-subject, increasing random noise and reducing the power detect any 
true effects. However, because reward processing is an iterative learning operation, the parallel-arm 
between-subject design confers the advantage of minimising any learning effects within subjects.  
Thirty-three CHR subjects were recruited from services in England and nineteen healthy controls (HC). 
CHR subjects were randomised to CBD (CHR-CBD, n=16) or placebo (CHR-PLB, n=17). Subjects were 
asked to abstain from psychoactive substances prior to scanning. Psychopathology was assessed by 
trained interviewers using the Comprehensive Assessment of the At-Risk Mental State. Drug use was 
assessed by urine sample and self-reported Cannabis Experiences Questionnaire (Barkus, Stirling et al. 
2006). All subjects underwent the same MRI scanning procedure in the same scanner including the 
two consecutive runs of the MIDT. Blood samples were taken for plasma CBD analysis before and after 
the MRI scan. The MIDT consisting of 48 trials randomised to 4 anticipation conditions of win 20p, win 
£1, lose £1 and neutral. Behavioural performance data were collected to assist interpretation of 
imaging data, including mean monetary reward (£GBP), accuracy (% response on target), reaction time 
(ms), false-starts (premature action initiation) and any trial responses (attention, %). Imaging data 




and loss were combined into a ‘motivational salience’ condition subsequently contrasted with the 
neutral condition within each group. Between group pairwise analysis was initially employed, focusing 
on (1) differences between CHR-PLB and HC to detect differences between health and the CHR state, 
and (2) CHR-PLB and CHR-CBD to detect the effect of CBD in the CHR state. The groups were then 
compared by ANOVA to test for any linear relationship. Activity in surviving clusters was then co-


























The neural substrate of reward anticipation in health: a meta-analysis 
of fMRI findings in the monetary incentive delay task.  
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In the “The Neural Substrate of Reward Anticipation in Health: A Meta-Analysis of fMRI Findings in the 
Monetary Incentive Delay Task”, both group map data and coordinate-based data were initially 
combined in an ‘omnibus analysis’. On post-hoc analysis, significant bias was observed in the main 
peaks for both anticipation win-vs-neutral (AWAN) and anticipation lose-vs-neutral (ALAN) contrasts 
(Supplementary Fig. 1, Supplementary Table 4) leading to exclusion of all coordinate-based data. 
In this addendum, we explore this bias and directly compare group map data with coordinate-based 
data using methods detailed in the section “Data Analysis: Seed-Based D Mapping” in the article. 
 
Bias in coordinate-based data 
There were 18 studies (n=382) for AWAN and 10 studies (n=228) for ALAN with coordinate-based data 
(see Table 1). As in the original paper, mean maps were generated and thresholded at the validated 
default settings (p< 0.005, SDM-z> 1.0, k>10 voxels). Bias was then estimated by funnel plot (effect 
size on the x-axis, standard error on the y-axis) and asymmetry assessed by Egger’s test.  
 
Table 1. Anticipation win and lose versus neutral main peaks using coordinate-based data 
Peak MNI coordinate SDM-z P FDR Voxels Anatomical Description Egger’s test p 
AWAN activation (18 studies, n=382) 
-14,10,0 5.658 ~0 <0.0001… 10700 Left putamen 0.048 
4,4,28 4.121 ~0 <0.0001… 3458 Right anterior cingulate 0.541 
-24,-42,-26 3.611 <0.0001 0.0001 869 Left cerebellum anterior lobe* 0.046 
12,-64,6 3.461 0.0001 0.0002 79 Left striate area 0.642 
-40,26,0 2.937 0.0017 0.0020 24 Left inferior frontal gyrus orbital part 0.043 
18,-72,-22 2.811 0.0029 0.0029 14 Right cerebellum posterior lobe* 0.414 
ALAN activation (10 studies, n=228) 
0,12,10 6.035 ~0 <0.0001… 7195 Left anterior cingulate gyrus** 0.869 
-6,16,22 4.044 ~0 <0.0001… 248 Left anterior cingulate gyrus 0.578 
-6,-60,0 2.603 0.0023 0.0027 14 Left lingual gyrus 0.297 
36,56,8 2.565 0.0027 0.0027 11 Right middle frontal gyrus 0.505 
p< 0.005, SDM-z> 1.0, k>10 voxels, MNI (Montreal Neurological Institute), SDM-z (Signed Differential Mapping z-score), FDR (false discovery 





In the AWAN group, three peaks proved significant demonstrating evidence of bias, located in the left 
putamen, left cerebellum anterior lobe and left inferior frontal gyrus orbital part. No peaks 
demonstrated bias in ALAN. 
 
Between-group linear comparison 
The automated linear model analysis described in the methods section of the main paper was used to 
detect any major differences between group map data and coordinate-based data in both AWAN and 
ALAN.  
 
Table 2. Between-group linear comparison of group map data minus coordinate-based data for the 
contrast anticipation win versus neutral 
Peak MNI coordinate SDM-z P FDR Voxels Anatomical Description 
-8,-4,54 8.508 ~0 <0.0001… 17237 Left superior frontal gyrus medial part 
36,48,26 6.241 ~0 <0.0001… 555 Right middle frontal gyrus 
40,-56,-8 5.524 ~0 <0.0001… 191 Right inferior temporal gyrus 
-42,-58,-6 5.612 ~0 <0.0001… 165 Left inferior temporal gyrus 
18,-18,16 5.209 ~0 <0.0001… 161 Right caudate/ventral lateral thalamic 
nuclei 
24,2,6 6.558 ~0 <0.0001… 80 Right putamen 
-22,2,6 6.918 ~0 <0.0001… 71 Left putamen 
16,-44,-18 5.537 ~0 <0.0001… 59 Right cerebellum anterior lobe* 
-48,-70,34 -5.635 ~0 <0.0001… 1888 Left angular gyrus 
54,-64,30 -5.602 ~0 <0.0001… 1295 Right angular gyrus 
p< 0.005, SDM-z> 5.0, k>10 voxels, MNI (Montreal Neurological Institute), SDM-z (Signed Differential Mapping z-score), FDR (false discovery 
rate), *Talairach client 
 
For the contrast AWAN, extensive areas were found to be significantly different between the two 
forms of data. In order to meaningfully interpret the results, the z-score ≥ 5.0 threshold was applied 
once again (see Table 2, Figure 1). Areas differing between the two sets of data overlapped with 
locations identified in the main paper for activation (superior and middle frontal gyri, inferior temporal 





Figure 1. Between-group linear comparison of group map data minus coordinate-based data for the 
contrast anticipation win versus neutral  
 
Red- relative activation, blue- relative deactivation 
 
Table 3. Between-group linear comparison of group map data minus coordinate-based data for the 
contrast anticipation lose versus neutral 
Peak MNI coordinate SDM-z P FDR Voxels Anatomical Description 
0,10,14 -5.179 ~0 <0.0001… 139 Left caudate* 
p< 0.005, SDM-z> 5.0, k>10 voxels, MNI (Montreal Neurological Institute), SDM-z (Signed Differential Mapping z-score), FDR (false discovery 
rate), *nearest grey matter structure 
 
Applying the same threshold to ALAN did not yield such extensive regions, but notably a cluster 
including the left caudate was robustly identified as being relatively less activated in group map data 
(see Table 3, Figure 2).  
 
Figure 2. Between-group linear comparison of group map data minus coordinate-based data for the 
contrast anticipation lose versus neutral 
 





There is some evidence of bias in the literature in reporting reward anticipation in the MIDT, which is 
mitigated by exclusive use of group-map data. Group maps contain far more data from across the 
brain including both activation and deactivation as standard, whereas coordinate-based data contains 
information on far fewer voxels and may exclude deactivation. Group maps contain larger sample sizes 
and are therefore subject to less sampling error and greater statistical power than coordinate-based 
data maps. In addition, because the coordinate-based data is thresholded, there is an increased 
probability of Type II error (rejecting a real effect) within maps. 
The findings in this addendum corroborate those of Salimi-Khorshidi et al who found poor similarity 
between image based meta-analysis (IMBA) and coordinate-based meta-analysis (CBMA) within the 
same dataset (Salimi-Khorshidi, Smith et al. 2009). The results presented here infer that there is 
considerable type II error and sampling error in CBMA of the MIDT, which may well apply to other 
cognitive task-fMRI CBMA’s. This is not to say that findings of CBMA are incorrect, but that they may 
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For the discussion, the article titles for chapters 3 and 4 are abbreviated as such: 
 Chapter 3: “The neural substrate of reward anticipation in health: a meta-analysis of fMRI 
findings in the monetary incentive delay task” is referred to as the MS meta-analysis 
 Chapter 4: “Cannabidiol attenuates insular dysfunction during motivational salience 
processing in subjects at clinical high risk for psychosis” is referred to as the CBD study 
 
Summary of findings 
In this thesis, we set out to determine the neural substrate of motivational salience in healthy adults 
using fMRI, whether motivational salience is affected in the clinic high-risk (CHR) for psychosis state 
and the effect of modulation by cannabidiol. In the MS meta-analysis, we established a definitive and 
robust map of motivational salience in healthy adults based on original group map data capturing the 
anticipation phase of the Monetary Incentive Delay Task (MIDT). We also established that the core 
salience network (SN), comprising the anterior cingulate gyrus (ACG) and insula, is fundamental to 
motivational salience (MS). In the experimental CBD study, we demonstrated functional differences 
during MS between CHR participants and matched healthy controls (HC) in the core SN. We found 
abnormal activation in the core SN and superior frontal gyrus (SFG) medial part in CHR subjects, and 
attenuation of these regions by acute administration of oral CBD associated with change in 
behavioural performance toward. 
 
The MS meta-analysis 
This was the first published fMRI meta-analysis exclusively using original group map data to study the 
MIDT and MS, and the first to report regions of both relative activation and deactivation. We have 
robustly shown more extensive involvement of cortical and subcortical regions than has been reported 
before, and we have established a fundamental role for the SN in MS. From a total of fifteen 
international whole-brain group maps (n=346), we have found that MS involves activity in the 
striatum, the SN, the central executive network (CEN), default network (DN) and the cerebellum.  
The SN, DN and CEN have been labelled the ‘three core neurocognitive networks’, because they are 
intrinsically coupled and engaged during waking rest and task activity (Menon 2011). The SN is thought 
to detect salient events or stimuli and facilitate switching between the DN (waking rest) and the CEN 
(working memory, attention) (Sridharan, Levitin et al. 2008, Goulden, Khusnulina et al. 2014).The 




Joseph et al. 2010) and has been coined the ‘alerting insula and updating cingulate’, whereby the 
anterior insula signals the presence of behaviourally relevant events to the dACG which updates 
attention settings (Han, Eaton et al. 2018).  
Regarding the CEN, we found robust and consistent activation in the bilateral dorsolateral prefrontal 
cortex (PFC) and bilateral superior parietal lobule, with a mix of activation and deactivation in angular 
and supramarginal gyri. Regarding the DN, this has been theorised to consist of three functional 
subdivisions, the ‘core’ posterior cingulate concerned with self-referential processes, the ‘medial 
temporal subsystem’ concerned with episodic memory and contextual retrieval, and the ‘dorsal 
medial subsystem’ involved with semantic processing (Andrews-Hanna, Smallwood et al. 2014). The 
core posterior cingulate was consistently activated in loss and reward. However, activity in the ‘medial 
temporal subsystem’ was heterogenous, specifically in the ventromedial prefrontal cortex, 
parahippocampal gyri and hippocampi. Within the ‘dorsal medial subsystem’, the bilateral 
supplementary motor area (SMA) converging with dorsomedial PFC were consistently activated with 
heterogenous activity in the lateral temporal cortex.  
We also confirmed a role for the cerebellum in MS, with heterogenous activity in both reward and loss 
conditions. There is increasing evidence of cerebellar involvement in reward processing. Climbing 
fibres (projecting from the inferior olivary nucleus of the medulla to deep cerebellar nuclei and 
Purkinje cells) encode prediction error signal (Ohmae and Medina 2015) and expected reward valence 
(Larry, Yarkoni et al. 2019), and both climbing fibres and anterior cerebellar granule cells encode 
reward expectation (Wagner, Kim et al. 2017, Kostadinov, Beau et al. 2019). Recently, direct 
projections have been found from deep cerebellar nuclei to the ventral tegmental area in mice (Carta, 
Chen et al. 2019) linking the cerebellum to mesostriatal projections. 
Comparison of anticipation of reward and loss revealed greater relative deactivation of the left inferior 
frontal gyrus (IFG) orbital part in anticipation of reward- suggesting a role in valence processing. The 
orbital part of the IFG lies adjacent to the lateral orbital gyrus and can be considered part of the lateral 
orbitofrontal cortex (LOFC). The LOFC has been found to encode predicted reward value (Howard, 
Gottfried et al. 2015), reward value on consummation (Sescousse, Redouté et al. 2010), and is involved 
in decisions based on reward value and probability (Rogers, Owen et al. 1999). It has also been 
reported that the LOFC is active on presentation of novel stimuli encoding reward, yet suppressed on 
repeated presentation of the same stimulus, thereby encoding a representation of that stimulus 
(Klein-Flügge, Barron et al. 2013). Our findings concur with suppression on repeated presentation, but 





A second significant peak was identified in the left ACG (though beneath publication threshold) 
showing overall activation, relatively greater in anticipation of reward than loss. The dACG is sensitive 
to change in reward valence (Bush, Vogt et al. 2002), has a role in performance monitoring (Holroyd, 
Nieuwenhuis et al. 2004), enhancing attention to task relevant stimuli (Weissman, Gopalakrishnan et 
al. 2004) and optimising cognitive performance dependent on predicted demand informed by 
previous behaviour (Sheth, Mian et al. 2012). Recently it has been shown that the dACG may compare 
past positive and negative rewards representing predicted reward (Wittmann, Kolling et al. 2016). The 
dual roles of reward processing and modulation of cognition have been united in the ‘expected value 
of control (EVC) theory’, whereby dACG evaluates expected future benefits from given cost of control 
intensity and is involved in downstream control allocation and behaviour (Shenhav, Cohen et al. 2016). 
Our findings support the reported sensitivity of the dACG to valence in the context of MS, which may 
in turn coordinate attentional resources and facilitate switching from the DN to CEN.  
The inferior frontal gyri are also critical in response inhibition, a core component of the CEN and the 
reward anticipation phase of the MIDT when waiting for the target to present.  There is a body of 
evidence for the role of the IFG in response inhibition. It has been hypothesised that the right IFG 
applies a brake to motor response which may be influenced by salience (Aron, Robbins et al. 2014). 
There is also neuropsychological evidence of a specific role for the left IFG, as lesions have been shown 
to impair response inhibition in the Go/No go task (Swick, Ashley et al. 2008).  
In summary, during MS, the dACG is relatively activated and the LOFC relatively deactivated. This may 
represent a dACG-LOFC axis encoding learned reward valence. During anticipation of reward, dACG 
activation and LOFC deactivation are more significant than during anticipation of loss. Could greater 
dACG activation coordinate suppression in the LOFC associated with differential motor response 
inhibition? 
Finally, as discussed in the addendum to Chapter 3, we demonstrated evidence of bias and type II 
error in the literature reporting reward anticipation in the MIDT which could extend to all published 
fMRI coordinate-based meta-analyses (CBMA). We therefore propose that methodological 
consideration be given to prioritising image-based meta-analyses (IBMA) in future to avoid ‘missing 
the big picture’. 
 
The CBD study 
In this double-blind randomised placebo-controlled parallel-arm study, thirty-three antipsychotic-




underwent the MIDT during fMRI. Nineteen age and sex-matched healthy adults were recruited as 
controls. During analysis, the anticipation conditions of reward and loss were combined to create a 
condition of motivational salience. Results were analysed at exploratory whole-brain level and within 
hypothesis-driven a priori regions-of-interest (ROI) using masks encompassing: 1) hippocampus-
midbrain-striatum, and 2) core SN (bilateral ACG and insulae). Two pair-wise comparisons were 
analysed between i) HC and CHR-PLB and ii) CHR-PLB and CHR-CBD. A linear relationship between the 
three groups was investigated by 3-way ANOVA. Correlations with behavioural performance were 
restricted to ANOVA-generated clusters. Significant differences in all tests were identified in the core 
SN and at whole-brain level but were notably absent in the hippocampus-midbrain-striatum.  
Within the core SN, compared to HC, CHR-PLB subjects demonstrated increased activity in the bilateral 
frontal operculae (FO) and left insula/parietal operculum (Ins/PO). In the whole-brain analysis, CHR-
PLB exhibited increased activation in the left superior frontal gyrus (SFG) medial part, left IFG/FO and 
left superior temporal/supramarginal gyri. 
Compared to CHR-CBD, left Ins/PO activation was again increased in CHR-PLB. At the whole-brain 
level, CHR-PLB had relatively increased activity in the right SFG lateral part and decreased activity in 
the right cerebellum posterior lobe. 
A linear relationship was present between the three groups in the core SN and whole-brain levels, but 
not in the hippocampus-midbrain-striatum. Two clusters located in the left FO and left Ins/PO were 
significant within the core SN and one cluster in the left SFG medial part at whole-brain level. 
Surprisingly, we did not find any differences between the three groups in the ACG, given the solid 
body of evidence for pathology in psychotic disorders. In all three clusters, activation was greatest in 
CHR-PLB, least in HC, with CHR-CBD intermediate, suggesting that abnormal hyperactivity in CHR-PLB 
was attenuated by CBD.  
In the HC group, there was a negative correlation between left Ins/PO activation and reaction time in 
the salience condition, directly implicating this area in the detection of salience and preparation of a 
motor response. Furthermore, in the CHR-PLB group, left Ins/PO activation correlated positively with 
positive psychotic symptoms and negatively with mean difference in reaction time, linking abnormal 
psychopathology and impaired salience detection with hyperactivation in the same area of insular 
cortex.  
The insula is a region of cortex folded within the lateral sulcus bordering the frontal, temporal and 
parietal lobes. The areas of cortex covering and confluent with the insula are known as the frontal, 




hub of sensorimotor, visceral, interoceptive, cognitive and emotional information processing (Gogolla 
2017, Uddin, Nomi et al. 2017). Structural connectivity has shown extensive connections to cortical 
areas including frontal, parietal, temporal cortices and cingulate cortex (Ghaziri, Tucholka et al. 2017). 
Resting state functional connectivity suggests two regionally defined patterns of connectivity moving 
from anterior to posterior insula on a continuum (Tian and Zalesky 2018). The anterior insula has a 
pattern of connectivity to the ACG, middle frontal, inferior frontal, temporoparietal cortex and 
cerebellum, whereas the posterior pattern connects to posterior cingulate, sensorimotor and 
premotor cortex, SMA, temporal and occipital cortex (Cauda, D'Agata et al. 2011, Cauda, Costa et al. 
2012).  
Insula function within the salience network during task performance is typically considered to be 
lateralised to the right side, specifically to the right anterior insula (Cauda, Costa et al. 2012). However, 
we have found that differences between CHR-PLB and HC are predominantly lateralised to the left 
insula with associated activation of left SMA, inferior frontal and temporoparietal cortex. This could 
reflect abnormal activation of the DN during motivational salience in CHR subjects. It has been 
reported that functional connectivity is altered between the three core neurocognitive networks in 
schizophrenia (Manoliu, Riedl et al. 2013), and that dysconnectivity between the SN and DN may be a 
core deficit of early psychosis (O’Neill, Mechelli et al. 2018). Contralaterally, reduced functional 
connectivity between the midbrain and right insula has also been reported during reward 
consummation in psychosis (Gradin, Waiter et al. 2013). 
Administration of CBD attenuated the hyperactivation observed in the left Ins/PO of CHR associated 
with reduced activation of the right dorsolateral PFC and increased activation in the right cerebellum. 
This suggests modulation of connectivity by CBD in the insula, an effect previously reported in other 
brain areas during attentional salience (Bhattacharyya, Falkenberg et al. 2014). The dorsolateral PFC 
is part of the CEN and is known to exhibit dysfunction in schizophrenia (Lewis, Hashimoto et al. 2005). 
It has been reported that the dorsolateral PFC exerts an inhibitory influence on the anterior insula 
which in turn exerts an excitatory influence on the dorsolateral PFC forming a feedback loop between 
the SN and CEN which is diminished in schizophrenia (Palaniyappan, Simmonite et al. 2013).  
The cerebellum also falls within the anterior insula connectivity pattern. Cerebellar motor dysfunction 
has long been recognised in psychosis, but the role the cerebellum plays is relatively under-
investigated compared to regions such as the striatum (Bernard and Mittal 2014). The MS meta-
analysis confirmed cerebellar involvement in MS in health, and the CBD study has shown an effect of 
CBD on cerebellar activity in CHR. Furthermore, CB1 density is high in the cerebellum, including on 




CBD also attenuated hyperactivation of the left SMA, a region high in CB1 density (Hu and Mackie 
2015). Activation in this cluster positively correlated with reaction time in the salience condition, 
suggesting that attenuation of this region improved reaction time, despite the overall main effect of 
CBD slowing reaction times. The SMA is considered part of the DN and has also been linked to reward 
expectancy (Campos, Breznen et al. 2005). The SMA has been linked to motor readiness (Chen, 
Scangos et al. 2010), timing of motor response (Mita, Mushiake et al. 2009), behavioural response 
selection and inhibition (Simmonds, Pekar et al. 2008), motor planning, execution and sequence 
processing (Cona and Semenza 2017). CHR-PLB generated more premature motor responses (false-
starts) than both HC and CHR-CBD (trend level). Therefore, hyperactivation of the SMA in CHR may be 
involved in impaired timing or response inhibition leading to premature motor response in CHR, 
improved on administration of CBD. 
What does this tell us about the role of motivational salience in early psychosis? It is important to 
recall that the CHR state is not an established disorder, but a clinically heterogenous group of help-
seeking young adults experiencing mild symptoms akin to schizophrenia. As previously discussed, it 
could be that attenuated or brief limited psychotic symptoms may be representative of the severity 
of other non-psychotic disorders, especially in the young. In addition, the HC group were selected on 
the basis of low rates of substance use, and it is feasible that the differences that we have observed 
could be attributed to higher rates of substance use.  
It is important to consider that other neurotransmitter systems have also been implicated in 
motivational salience using the same paradigm of drug intervention during MIDT and fMRI. Most 
pertinent to psychosis is dopamine and the antipsychotic class of drugs. All antipsychotics share the 
pharmacodynamic property of D2R antagonism. ‘Typical’ first-generation antipsychotics primarily 
exert effects via potent dopaminergic antagonism and are more associated with extrapyramidal side 
effects, whereas ‘atypical’ second-generation antipsychotics target additional neurotransmitter 
systems such as serotonin and noradrenaline with fewer extrapyramidal side effects. Olanzapine (an 
atypical) has been shown to attenuate VS activation in healthy controls (Abler, Erk et al. 2007). 
However, VS hypoactivation is recognised during motivational salience in patients with schizophrenia 
(Radua, Schmidt et al. 2015). Atypical antipsychotics appear to both enhance VS activation compared 
to typicals (Juckel, Schlagenhauf et al. 2006, Schlagenhauf, Juckel et al. 2008) and normalise (Simon, 
Biller et al. 2010, Nielsen, Rostrup et al. 2012). This action may be related to activity in alternative 
neurotransmitter systems to dopamine, and in fact both the serotonin/noradrenaline reuptake 
inhibitor duloxetine and noradrenaline/dopamine reuptake inhibitor bupropion have been shown to 




2019). The theme of variation in striatal activation is common to these studies, however we found no 
difference in striatal activation on CBD administration. 
Therefore, we cannot draw any specific conclusion about the underlying aetiology of primary 
psychotic disorders, though we can offer insights into the relationship between symptoms and 
motivational salience. In the same vein, we cannot infer that CBD may prevent the onset of a psychotic 
disorder, but it may potentially alleviate symptoms. We can confirm that the endocannabinoid system 
is involved in motivational salience and that CBD may have therapeutic properties in improving 
motivational salience in CHR. 
 
Limitations and methodological considerations 
The fMRI/cognitive task paradigm 
The main limitation of fMRI is a lack of understanding the mechanism of neurovascular coupling and 
the haemodynamic response, which itself varies across the cortex. On average, in 1mm3 of cortex, 
there are up to 30,000 neurons, probably slightly more glial cells, 109 synapses, 4km of axon and 0.4km 
of dendrites (Logothetis 2008, von Bartheld, Bahney et al. 2016). Thus each fMRI voxel represents a 
highly complex population of cells and connections. The haemodynamic response is likely a function 
of net excitation/inhibition in local excitatory-inhibitory micro-networks of neurons (Logothetis 2008). 
The relationship between neuronal activity, neurovascular coupling, haemodynamics and the BOLD 
signal have been described by a generative model, though this is beyond the scope of this thesis 
(Havlicek, Roebroeck et al. 2015). 
Contrasting within-task conditions is based on the assumption that brain function consists of discrete 
cognitive processes, and that subtracting one condition from another, such as subtracting anticipation 
neutral from anticipation win, equates to the removal of discrete cognitive processes of interest. 
Furthermore, in fMRI, contrasting conditions relies on the idea of ‘pure insertion’, that such cognitive 
function evokes unique brain activity which is independent of other cognitive functions and activity in 
the brain. However, the brain is a non-linear system and this assumption has been experimentally 
challenged and critiqued (Friston, Price et al. 1996). 
 
MS meta-analysis 
We did not register the protocol for the meta-analysis in advance, for example with the National 




(PROSPERO- https://www.crd.york.ac.uk/prospero/). There were also only enough resources for a 
single-rater for study selection, increasing risk of selection bias. Due to the extensive findings, we 
introduced the extremely conservative ‘z5’ concept as a post-hoc threshold borrowed from other 
scientific disciplines. This post-hoc analysis introduced a risk of confirmation bias during interpretation 
and an increased type II error, although all results at the original threshold are published in the 
supplementary material. Therefore, the main function of our maps will be to provide guidance for 
exploration of the role of more refined areas the brain in the context of motivational salience. To that 
effect, we have generated a number of masks available for use as “data-based ROI’s” in future analysis. 
There were insufficient data for analysis of behavioural performance and highly variable parameters 
in image acquisition and analysis preventing any meaningful regression analyses and identification of 
confounding variables. It’s also important to recognise we analysed secondary ‘monetary’ reward, and 
the anticipation conditions of the MIDT are not designed to capture other important elements of 
reward processing such as prediction error signal, consummation or learning. 
Finally, the findings have been interpreted in the context of brain networks owing to the sheer number 
of peaks of activation, but the meta-analysis itself was a mass univariate analysis, not a multivariate 
analysis of functional connectivity designed to elicit network changes. This could introduce a further 
risk of confirmation bias. 
 
CBD study 
For fMRI, our sample sizes were small resulting in low statistical power and probable inflation of brain-
behaviour correlation, particularly at whole-brain level (Cremers, Wager et al. 2017). A recent analysis 
of data from the Human Connectome Project demonstrated that most fMRI studies are insufficiently 
powered to detect reasonable effect sizes despite improvements in power over time (Poldrack, Baker 
et al. 2017). However, it has been argued that pharmaco-fMRI studies have detected consistent and 
reproducible effects in disease specific networks (Wandschneider and Koepp 2016). In the CBD study, 
we combined conditions of reward and loss anticipation to increase power, but this necessarily 
prevented investigation of valence and any differences between reward-approach behaviour and loss-
avoidance behaviour.  
Moreover, the use of placebo in the CHR-PLB sample introduced a major confounder when comparing 
with HC who were not subjected to any intervention. In the MS meta-analysis, we reported significant 
placebo effect in the anticipation phase of the meta-analysis (Supplementary Fig 4, Supplementary 




we could have administered placebo to the HC group or recruited a further sample of CHR subjects 
without placebo. However, this was not practicable, as there are ethical implications in the first 
instance, and adopting the second scenario would have necessarily reduced the overall CHR sample 
size due to recruitment limitations. 
 
Implications for clinical practice 
The MS meta-analysis shows that extensive cortical, subcortical and cerebellar regions are involved in 
motivational salience and reward processing, particularly the ‘three core neurocognitive networks’. 
This provides a neurocognitive basis for investigating differences in psychiatric disorders where 
reward processing is involved and for pharmaco-fMRI trials of therapeutic agents.  
The CBD study adds to existing literature on the complex relationship between cannabis and psychosis, 
suggesting a potential common neural substrate for substance use and psychosis within the salience 
network. Through cannabinoid modulation of motivational salience, the endocannabinoid system is 
implicated in psychopathology and reward processing abnormalities in psychosis.   
The development of CBD as a drug is potentially ground-breaking. Traditional dopaminergic 
antipsychotics are associated with major side effects including loss of cortical volume (Emsley, Asmal 
et al. 2017), extra-pyramidal and metabolic side effects. CBD could be the first effective non-
dopaminergic antipsychotic agent. In addition, the absence of findings in hippocampus-midbrain-
striatum, traditionally at the core of the aetiology and treatment of psychosis, may represent a 
paradigm shift from mesostriatal dopamine to alternative neurotransmitter systems and cognitive 
networks such as the salience network.  
The CBD study contributes to phase II evidence for the effectiveness of CBD as an antipsychotic. 
Pharmaco-fMRI studies offer the advantage of detecting effects on brain function without subjective 
symptom relief and with more consistent and objective data from smaller sample sizes 
(Wandschneider and Koepp 2016). Phase III trials principally demonstrate effectiveness, safety, side 
effects and comparison with other existing treatments. There are several patient groups where 
evidence warrants further phase III trials of CBD, particularly in early psychosis. The antipsychotic 
potential of CBD augurs well for the prevention and treatment of the high proportion first-episode 






In relation to future studies of the MIDT, we have generated data-based masks, as opposed to 
hypothesis-driven region-of-interest, available for the analysis of the anticipation phase. Regarding 
the methodology of future imaging meta-analyses, we have introduced the concept of the ‘z5’ 
threshold borrowed from other scientific disciplines. We have contributed the evidence in the 
literature of bias and Type II error in neuroimaging coordinate based meta-analyses, so that the design 
of future imaging meta-analyses should consider image-based meta-analysis (IBMA). Feedback data 
from the MIDT should be subject to IBMA. Other cognitive aspects of reward processing not directly 
captured in this MS meta-analysis or by the standard MIDT itself, such as value encoding, reward 
prediction error signal and learning also need further investigation, and subsequently, the functional 
connectivity for each aspect should be determined.  
Given the pre-eminence of striatal dopamine in theories of psychosis and reward processing, the 
relationship between the ‘three core neurocognitive networks’ and striatal dopamine deserves further 
scrutiny. Dopamine synthesis capacity has already been linked to functional connectivity in the 
salience network in healthy adults (McCutcheon, Nour et al. 2018).  
There should be further investigation of the potential common neural substrate of motivational 
salience and psychopathology, particularly the finding of impaired salience detection associated with 
insular hyperactivation. Functional connectivity between the identified regions might reveal an 
‘aberrant salience network’. Of specific relevance, von Economo neurons are found almost exclusively 
in the ACG and frontoinsular cortex (Watson, Jones et al. 2006, Fajardo, Escobar et al. 2008) and 
density is reduced in the ACG in early onset schizophrenia (Brüne, Schöbel et al. 2010). What role 
might these neurons play in CHR, psychopathology and motivational salience? 
The CBD study findings could be expanded by investigation of motivational salience using similar 
methodology in a longitudinal cohort of CHR focusing on subjects who transition to a psychotic 
disorder, or in a first-episode/early psychosis sample. It is also important to analyse the effect of 
continued treatment with CBD, in the CHR sample and others, as this is only an acute challenge.  
Perhaps the most significant contribution of this thesis to future research could be as background 
evidence for phase III clinical trials of CBD in psychosis to determine its efficacy, safety and tolerability 
profile. Finally, there needs to be further research into the role of the endocannabinoid system in 
severe mental illness, psychopathology and reward processing. Specifically relating to CBD, its effect 
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Supplementary Table 1. Available demographics for all 33 studies included in omnibus analysis including coordinate-based and group map data 
sources  
 










Smoking Alcohol Drugs Years 
education 
FSIQ SES Ethnicity 
De Leeuw (de 
Leeuw, Kahn et 
al. 2015) 












Spain Maps 18 37.4 (8.2) 
100 
100 
n/a n/a 0 
9.56 (2.2) n/a n/a n/a 
Funayama 
(Funayama, 
Ikeda et al. 
2014) 
Japan Maps 20 29.9 (n/a) 
60 
100 
n/a n/a n/a 
n/a n/a n/a n/a 
Kappel (Kappel, 
Lorenz et al. 
2014) 





h ± 284.2 n/a 
12.1 (1.4) 108 
(11.3) 
5.55 n/a 
Li (Li, Sescousse 
et al. 2014) 












13.2 (1.7) n/a n/a n/a 
Pecina (Pecina, 
Martinez-
Jauand et al. 
2014) 












Seidel et al. 
2014) 
Austria Maps 25 23.8 (3.6) 
48 
100 
n/a n/a n/a 
n/a n/a n/a n/a 
Costumero 
(Costumero, 
Spain Maps 44 23.4  (4.1) 
100 
98 
n/a n/a 0 









Hell et al. 2013) 
Netherlands Maps 11 21.2 (2.65*) 
100 
n/a 
0.06 cigs/day 13.2u/week 
22.6 times 
cannabis 
used in last 
year, other 
illicit 0.73 
n/a 105 (1.5) n/a n/a 
Kaufmann 
(Kaufmann, 
Beucke et al. 
2013) 
Germany Maps 19 34.9 (11.8) 
42 
84 
n/a n/a 0 last 3/12 
n/a 107 (12) n/a. n/a 
Saji (Saji, Ikeda 
et al. 2013) 
Japan Maps 18 29.6 (6.94) 
56 
100 
n/a n/a n/a 
n/a n/a n/a n/a 
Choi (Choi, Shin 
et al. 2012) 
Korea Maps 15 26.6 (4.29) 
100 
100 9.3 cigs/day 
(8 smokers) 0 0 
14.27 (1.4) 114 (7.1) n/a n/a 
Van Hell (van 
Hell, Jager et al. 
2012) 




(SD 8.4, 0-28) 
16.7 U/week 
(SD 8.7, 2-40) 
CU 17.9 times 
last 12/12 (SD 
13.4, 5-52), 
other SU 1.3 
/lifetime (SD 
1.6, 0-4) 
n/a 105 (6) n/a n/a 
Da Silva Alves 
(da Silva Alves, 
Schmitz et al. 
2011) 
Netherlands Maps 10 35.8 (10.4) 
100 
100 
n/a 0 0 
14.8 (2.3) n/a n/a n/a 
Nestor (Nestor, 
Hester et al. 
2010) 






used (SD 4.2) 7.8 (SD 1.4) 















16.1 (0.4) 123 (0.8) n/a n/a 
Damiano 
(Damiano, Aloi 
et al. 2014) 
USA Coords 31 23.58 (3.15) 
45 
100 










Kober et al. 
2012) 














Enzi (Enzi, Edel 
et al. 2012) 
Germany Coords 15 34.7 (8.3) 
53 
100 
n/a n/a n/a 
14.94 (1.9) n/a n/a n/a 
Wu (Wu, 
Samanez-Larkin 
et al. 2014) 
USA Coords 49 50 (16.5) 
47 
106 
n/a n/a n/a 
n/a n/a n/a n/a 
Kirk (Kirk, 
Brown et al. 
2014) 
USA Coords 44 36.5 (9.7) 
45 
n/a 
n/a n/a n/a 








Koehler et al. 
2014) 












11.35 (1.5) n/a n/a n/a 
Weiland 
(Weiland, 
Heitzeg et al. 
2014) 









6/12 to CNS 
prescription 
or illicit drug 
n/a n/a n/a n/a 
Treadway 
(Treadway, 
Buckholtz et al. 
2013) 
USA Coords 38 22 (4**) 
53 
n/a 
n/a n/a n/a 
n/a n/a n/a n/a 
Vaidya (Vaidya, 
Knutson et al. 
2013) 
USA Coords 18 27.72 (1.36) 
50 
100 
n/a n/a n/a 
n/a n/a n/a n/a 
Ossewaarde 
(Ossewaarde, 
Verkes et al. 
2011) 






n/a n/a n/a n/a 
Ossewaarde 
(Ossewaarde, 
Qin et al. 2011) 
Netherlands Coords 13 20 (1.8) 
0 
100 
n/a n/a n/a 











(SD 4.27) n/a 








et al. 2003) 
USA Coords 12 31 (n/a) 
50 
100 
n/a n/a n/a 
n/a n/a n/a n/a 
De Greck (de 
Greck, Scheidt 
et al. 2011) 
Germany Coords 20 37 (10.6) 
40 
80 
n/a n/a n/a 
n/a n/a n/a n/a 
Spreckelmeyer 
(Spreckelmeyer, 
Krach et al. 
2009) 




smoking" n/a n/a 
n/a n/a n/a n/a 
Knutson 
(Knutson, Bhanji 
et al. 2008) 











6/12, no Hx 
substance 
dependence 
n/a n/a n/a n/a 
Knutson 
(Knutson, Fong 
et al. 2001) 
USA Coords 9 26.45 (5.85) 
22 
100 
n/a n/a n/a 
n/a n/a n/a n/a 
Knutson 
(Knutson, 
Adams et al. 
2001) 
USA Coords 8 31 (n/a) 
50 
100 
n/a n/a n/a 
n/a n/a n/a n/a 













Supplementary Table 2: Monetary incentive delay task parameters for all 33 studies included in omnibus analysis including coordinate-based 






























De Leeuw (de 
Leeuw, Kahn et 
al. 2015) 






€0.2, 3 N 8000 120 960 500 2000-2250 100 2000-
4000 
1500 2000-4000 75 AW, AL, 
Funayama 
(Funayama, 
Ikeda et al. 
2014) 
¥20, 100, 500 Y (2 
week 
washout) 
. 180 . 2000 2000-2500 160-470 1130-
1940 
1900 . 66 AW, AL, FWH, FWM, FLH, 
FLM 
Kappel (Kappel, 
Lorenz et al. 
2014) 
*0.2, 1, 5 N 6000 144 1320 250 2000-2500 160-260 . 1650 . 66 AW 
Li (Li, Sescousse 
et al. 2014)* 
€1,2,3,10,11,12 N . 171 . 2500 1500-4500 1000 . 1500 2000-5000 . AW, FWH, FWM 
Pecina (Pecina, 
Martinez-
Jauand et al. 
2014) 
USD $0.2, 1, 5 N 6000 144 . . . . . . . . AL 
Pfabigan 
(Pfabigan, 
Seidel et al. 
2014) 
€2 N . 100 . 1000 2000-2500 264+/- 
 






€0.2, 3 N . 120 960 500 2000-2250 100 2000-
4000 
1500 2000-4000 . AW, AL 
Jansma 
(Jansma, van 
Hell et al. 2013) 
€0.1, 5 Y (2 
week 
washout) 
. 44 711 500 4300-
10300 






Beucke et al. 
2013) 
€0.1, 0.6, 3 N 11600 144 696 250 3740-4240 150-500 1420-
1720 
1870 3280-3780 66 AW, AL, FWH, FWM, FLH, 
FLM 
Saji (Saji, Ikeda 
et al. 2013) 
¥0, 100, 300 Y (1 
week 
washout) 
4370 144 780 250 2000-2500 160-260 . 1650 1000 66 AW, AL 
Choi (Choi, Shin 
et al. 2012) 
₩1000 N . . 1076.4 350 4180-4480 200-500 . 1500 5170-9850 . AW, AL 
Van Hell (van 
Hell, Jager et al. 
2012) 
€0, 2 Y (2 
week 
washout) 
8000 48 . . 4300-
10300 
. . . 0-30000 50 AW, FWH 
Da Silva Alves 
(da Silva Alves, 
Schmitz et al. 
2011) 
€0.2, 1, 5 Y (8 day 
washout 
6000 144 6000 250 2000-2500 160-260 . 1650 5000 66 AW, AL 
Nestor (Nestor, 
Hester et al. 
2010) 
€0, 0.5 N 6000-
18000 
81 1020 2000-8000 
(stimulus merged with 
anticipation) 




et al. 2014) 
USD $1 N 12000 80 . 2000 2000-2500 500 . 3000 . 67 AW 
Balodis 
(Balodis, Kober 
et al. 2012) 
USD $1, 5 N 12000 110 1200 1000 3000-5000 . 4000-
6000 
1200 . 66 AW, AL 
Enzi (Enzi, Edel 
et al. 2012) 
€0.1, 0.6, 3 N . 90 . 250 3740-4240 160-360 1500-
2200 
1650 4000 67 AW, AL 
Wu (Wu, 
Samanez-Larkin 
et al. 2014) 
USD $0.50, 5 N 10000 90 . 2000 2000-2500 150-500 . 2000 2000-6000 66 AW, AL 
Kirk (Kirk, 
Brown et al. 
2014) 





Koehler et al. 
2014) 
€1 N 9500 75 712.5 500 2000-4500 150-500 1000-
3000 
1500 4000-7000 67 AW, AL 
Weiland 
(Weiland, 
Heitzeg et al. 
2014) 
USD $0.20, 1, 5 N 6000 72 2x300 2000 2000 200-300 1700-
1800 






Buckholtz et al. 
2013) 
USD $0.2, 1, 5 N . 180 4x464 1000 2000-2500 160-260 . 1650 . 66 AW, AL, FWH, FLM 
Vaidya (Vaidya, 
Knutson et al. 
2013) 
USD $.20, $1 
and $5.00 
 . 162 3x600 . . . . . 4000 66 AW 
Ossewaarde 
(Ossewaarde, 
Verkes et al. 
2011) 
€1 N 10000 
(mean) 
50 750 3500-8500 










500 . 33 AW 
Ossewaarde 
(Ossewaarde, 
Qin et al. 2011) 
€1 N 10000 
(mean) 
50 750 3500-8500 














€0.1, 0.6, 3 N 7690 144 840 250 2250-2750 200-1000 . 1650 3530 67 AW, AL 
Knutson 
(Knutson, Fong 
et al. 2003) 
USD $0.20, 1, 5 N 6000 144 2x432 250 2000-2500 160-260 . 1650 . 66 AW, AL 
De Greck (de 
Greck, Scheidt 
et al. 2011) 
€1 N . 180 1890 250 2250-2750 200-500 . 1650 4000-5000 66 AW 
Spreckelmeyer 
(Spreckelmeyer, 
Krach et al. 
2009) 
€0.20, 1, 3 N . 88 840 240 2250-2750 160-260 . 1650 2500-5000 66 AW 
Knutson 
(Knutson, 
Bhanji et al. 
2008) 
USD $0.20, 1, 5 N 6000 180 1080 250 2000-2500 160-360 . 1650 . 66 AW, AL 
Knutson 
(Knutson, Fong 
et al. 2001) 
USD $1 N 6000 54 324 250 2000-2500 160-260 . 1650 . 66 AW 
Knutson 
(Knutson, 
Adams et al. 
2001) 




* uncertainty included in anticipation (probability of reward if successful 25, 75, 100%, and ‘low’ or ‘high’ intensity monetary reward), reaction to target based on visual discrimination within fixed time, not speed 
reaction time; AW (anticipation win), AL (anticipation lose), FWH (feedback win hit), FWM (feedback win miss), FLH (feedback lose hit), FLM (feedback lose miss) 
 
Supplementary Table 3: fMRI data acquisition and analysis parameters for all 33 studies included in omnibus analysis including coordinate-based 
and group map data sources 
 
 Scanner Sequence Strength 
/Tesla 










De Leeuw (de 
Leeuw, Kahn et 
al. 2015) 








Siemens Avanto T2 * gradient 1.5 2000 30 SPM8 8 30 3.5 (3x3x3mm) n/a n/a 
Funayama 
(Funayama, 






GE-EPI 1.5 2000 40 SPM8 8 28 5 (2x2x2mm) n/a n/a 
Kappel (Kappel, 
Lorenz et al. 
2014) 
GE Signa  T2*-weighted in-/out-spiral pulse  3 2300 27 SPM8 . 29 . . n/a n/a 
Li (Li, Sescousse 
et al. 2014) 
Siemens Sonata GE-EPI 1.5 2500 60 SPM2 10 26 . 3.4x3.4x4mm n/a n/a 
Pecina (Pecina, 
Martinez-




T2* weighted pulse sequence (single-shot 
combined spiral in/out, GE) 
3 2000 30 SPM8 6 29 4 . n/a n/a 
Pfabigan 
(Pfabigan, 
Seidel et al. 
2014) 
Siemens TIMTrio Gradient-recalled EPI-sequence with 
distortion correction 












Hell et al. 2013) 





Beucke et al. 
2013) 
Siemens Sonata GE-EPI 1.5 1870 40 SPM8 8 33 . 3x3x3.5mm n/a n/a 
Saji (Saji, Ikeda 





GE-EPI 1.5 2000 40 SPM8 8 28 5 (2x2x2mm) n/a n/a 
Choi (Choi, Shin 
et al. 2012) 
Siemens Avanto GE-EPI 1.5 2340 52 SPM8 4 25 . (3x3x3mm) n/a n/a 
Van Hell (van 






SENSE-PRESTO echo-shifting sequence 3 22.5 33.2 SPM5 8 40 . 4mm isotropic 
voxel 
n/a n/a 
Da Silva Alves 
(da Silva Alves, 
Schmitz et al. 
2011) 
Philips Intera T2*-weighted GE-EPI 3 2000 30 SPM5 8 35 3 3x3x3mm n/a n/a 
Nestor (Nestor, 









32 3.5 . n/a n/a 
Damiano 
(Damiano, Aloi 
























et al. 2012) 
Siemens 3 Tesla 
scanner (Trio; 
Siemens AG) 








Enzi (Enzi, Edel 











et al. 2014) 






Brown et al. 
2014) 



















T2*-weighted single shot combined spiral 
in/out sequences 




Buckholtz et al. 
2013) 








Knutson et al. 
2013) 

















Verkes et al. 
2011) 





Qin et al. 2011) 
Siemens TIM 
Trio  






















GE 1.5 2000 40 AFNI 4 22 3.8 3.75x3.75mm 
inplane 
resolution 
Uncorrected p<0.0001  
De Greck (de 
Greck, Scheidt 

















EPI 1.5 2000 50 SPM5 6 22 3.8 4x4x4mm Corrected FWE p<0.05 
Knutson 
(Knutson, 







T2*-sensitive in-/out- spiral pulse 
sequence 
1.5 . 40 AFNI 4 24 4 4mm3 Uncorrected P<0.0001 
Knutson 
(Knutson, Fong 























TR (acquisition time), TE (echo time), FWHM (full width at half maximum), FWE (family-wise error corrected), FDR (false discovery rate) 
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Supplementary Figure 1: Funnel plots for the highest peaks in AWAN and ALAN with Egger’s 
test for asymmetry 
 
Anticipation win-vs-neutral: peak 1 for all 33 studies included in omnibus analysis including coordinate-
based and group map data with effect size on the x-axis, standard error on the y-axis and Egger’s test 
beneath 
 













Anticipation win-vs-neutral: peak 1 for all 14 studies involving group map data with effect size on the x-
axis, standard error on the y-axis and Egger’s test beneath  
 
Egger test: Bias: -0.23, t: -0.12, df: 12, p=0.910 
Anticipation win-vs-neutral: peak 2 for all 33 studies included in omnibus analysis including coordinate-




Egger test: Bias: 2.96, t: 2.97, df: 30, p=0.006 
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Anticipation win-vs-neutral: peak 2 for all 14 studies involving group map data with effect size on the x-
axis, standard error on the y-axis and Egger’s test beneath  
 
Egger test: Bias: 0.24, t: 0.10, df: 12, p=0.919 
 
Anticipation lose-vs-neutral: peak 1 for all 33 studies included in omnibus analysis including coordinate-
based and group map data with effect size on the x-axis, standard error on the y-axis and Egger’s test 
beneath 
 
Egger test: Bias: 2.09, t: 2.08, df: 19, p=0.051 
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Anticipation lose-vs-neutral: peak 1 for all 11 studies involving group map data with effect size on the x-
axis, standard error on the y-axis and Egger’s test beneath
 

















Supplementary Table 4: Omnibus results for text coordinates and maps combined- main peaks 




SDM-z P FDR Voxels Anatomical Description Egger’s test p 
-14,10,0 8.552 ~0 0 15262 Left fundus region of putamen 0.007 
0,8,44 7.131 ~0 0 5872 Right anterior cingulate 0.006 
12,-64,6 5.062 ~0 0 839 Right striate area 0.960 
-24,-36,-26 4.603 0.000196099 0.000484 401 Left cerebellum anterior lobe, culmen* 0.928 
-58,-14,22 4.505 0.000356078 0.000738 86 Left postcentral gyrus 0.723 
52,0,42 4.113 0.002441049 0.003262 79 Right precentral gyrus 0.124 
26,-6,62 4.044 0.003349364 0.003965 26 Right superior frontal gyrus lateral part 0.174 
40,54,10 4.062 0.00312227 0.003785 21 Right middle frontal gyrus 0.691 
-20,-48,-34 4.082 0.002843618 0.003625 11 Left cerebellum, anterior lobe* 0.505 
-10,-24,40 3.967 0.00459826 0.004789 10 Left paracentral lobule 0.066 
44,-6,52 3.968 0.004567325 0.004789 10 Right middle frontal gyrus 0.313 
MNI (Montreal Neurological Institute), SDM-z (Signed Differential Mapping z-score), FDR (false discovery rate), *Talairach client 
 




SDM-z P FDR Voxels Anatomical Description Egger’s test p 
-52,-64,36 -3.723 ~0 0 5546 Left angular gyrus 0.405 
-22,24,48 -2.503 ~0 0 4953 Left superior frontal gyrus, lateral part 0.917 
56,-62,30 -3.417 ~0 0 1901 Right superior temporal gyrus 0.149 
10,-52,30 -2.521 ~0 0 1980 Right posterior cingulate 0.486 
-48,34,-12 -2.59 ~0 0 1094 Left inferior frontal gyrus, orbital part 0.936 
62,-4,-18 -1.555 ~0 0 1542 Right middle temporal gyrus* 0.734 
40,-12,14 -1.249 0.000005186 0.00000583 129 Right precentral gyrus 0.381 
-28,-14,-24 -1.001 0.000010312 0.0000103 76 Left parahippocampal gyrus 0.770 
0,-38,72 -1.226 0.000005186 0.00000583 76 Right postcentral gyrus* 0.789 



















P FDR Voxels Anatomical Description Egger’s test p 
16,8,10 7.27 ~0 0 12127 Right medial caudate/putamen 0.051 
-6,16,22 6.273 ~0 0 3500 Left anterior cingulate gyrus 0.554 
-14,-72,38 4.362 0.00023222 0.000483 593 Left parieto-occipital transition zone 0.270 
-6,-62,4 4.085 0.000851512 0.001352 367 Left occipital gyrus 0.786 
-30,-58,-8 4.674 0.000067115 0.000181 204 Left fusiform gyrus 0.343 
20,-68,42 4.251 0.000376761 0.000659 190 Right superior parietal lobule 0.301 
48,-2,42 3.841 0.002002418 0.002313 154 Right precentral gyrus 0.052 
34,52,4 4.267 0.000361264 0.000655 88 Right middle frontal gyrus 0.595 
4,-54,-10 3.88 0.001728892 0.002147 58 Right Cerebellum, Anterior Lobe, Culmen* 0.097 
38,46,20 3.842 0.001986921 0.002313 41 Right middle frontal gyrus 0.049 
52,12,32 4.055 0.000985742 0.001518 38 Right inferior frontal gyrus, opercular part 0.441 
22,-44,-8 3.93 0.001398563 0.001906 37 Right fusiform gyrus 0.854 
30,-82,14 3.913 0.00151211 0.001973 30 Right occipital gyri 0.161 
10,-78,12 3.847 0.001940489 0.002313 29 Right striate area 0.158 
24,-80,28 3.798 0.002353311 0.002665 28 Right parieto-occipital transition zone 0.446 
26,-20,-8 4.735 0.000046432 0.000135 17 Right claustrum 0.965 
-50,-36,38 3.675 0.003643513 0.003712 11 Left supramarginal gyrus 0.104 
MNI (Montreal Neurological Institute), SDM-z (Signed Differential Mapping z-score), FDR (false discovery rate), *Talairach client 
 




SDM-z P FDR Voxels Anatomical Description Egger’s test p 
-26,26,48 -2.168 ~0 0 4534 Left middle frontal gyrus 0.779 
-52,-66,32 -2.877 ~0 0 2334 Left superior temporal gyrus 0.174 
58,-62,28 -2.943 ~0 0 2031 Right superior temporal gyrus 0.553 
-6,-60,28 -2.178 ~0 0 1925 Left precuneus 0.194 
-60,-12,-16 -1.663 0.000005186 0.0000178 1081 Left middle temporal gyrus 0.410 
60,0,-18 -1.515 0.000020623 0.0000527 615 Right middle temporal gyrus 0.792 
-44,38,-18 -1.776 0.000005186 0.0000178 394 Left inferior frontal gyrus, orbital part* 0.739 
2,-56,66 -1.557 0.000010312 0.0000334 406 Right precuneus 0.048 
-16,-16,-26 -1.45 0.000025809 0.0000619 110 Left entorhinal cortex 0.097 
34,38,-12 -1.12 0.000185788 0.00031 60 Right lateral orbital gyrus 0.497 







Supplementary Table 5: Only Group Map Results 






P FDR Voxels Anatomical Description Egger’s 
test p 
2,0,62 9.798 ~0 0 25114 Right superior frontal gyrus, lateral part 0.910 
MNI 
coordinate SDM-Z P FDR Description 
-2,6,46 9.655 ~0 0 Left anterior cingulate 
-56,2,34 8.871 ~0 0 Left precentral gyrus 
-10,-4,54 8.749 ~0 0 Left paracentral lobule 
10,6,52 8.711 ~0 0 Right superior frontal gyrus medial part 
-56,2,24 8.652 ~0 0 Left precentral gyrus 
10,6,12 8.605 ~0 0 Right medial caudate 
8,14,2 8.554 ~0 0 Right nucleus accumbens 
-12,-2,50 8.511 ~0 0 Left superior frontal gyrus medial part 
10,12,6 8.417 ~0 0 Right medial caudate 
-10,4,14 8.416 ~0 0 Left medial caudate 
-22,4,8 8.362 ~0 0 Left putamen 
-14,6,12 8.268 ~0 0 Left medial caudate 
-56,0,40 8.261 ~0 0 Left precentral gyrus 
-12,10,34 8.153 ~0 0 Left anterior cingulate 
26,2,8 8.152 ~0 0 Right putamen 
-22,-2,54 8.145 ~0 0 Left superior frontal gyrus lateral part 
24,2,0 8.013 ~0 0 Right putamen 
-38,-10,42 7.988 ~0 0 Left middle frontal gyrus 
-4,8,6 7.937 ~0 0 Left fundus region of caudate 
-18,20,2 7.92 ~0 0 Left putamen 
-58,-18,44 7.837 ~0 0 Left postcentral gyrus 
-22,14,0 7.82 ~0 0 Left putamen 
-22,12,-4 7.758 ~0 0 Left prepiriform claustrum 
2,-28,-2 7.699 ~0 0 Right periaqueductal grey matter* 
-18,6,-2 7.661 ~0 0 Left putamen 
-54,-4,44 7.575 ~0 0 Left precentral gyrus 
-26,-24,58 7.524 ~0 0 Left postcentral gyrus 
-28,-24,64 7.456 ~0 0 Left postcentral gyrus 
14,-8,14 7.322 ~0 0 Right medial caudate 
-30,24,10 7.274 ~0 0 Left insular gyrus 
-6,4,34 7.252 ~0 0 Left anterior cingulate 
4,-28,-10 7.223 ~0 0 Right pretectal area 
-18,-66,36 7.217 ~0 0 Left precuneus 
22,-4,-4 7.167 ~0 0 Right putamen 
10,12,44 7.136 ~0 0 Right superior frontal gyrus medial part 
-6,16,26 7.121 ~0 0 Left anterior cingulate 
-12,8,0 6.997 ~0 0 Left fundus region of caudate 
-46,-8,54 6.9 ~0 0 Left precentral gyrus 
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-16,14,0 6.888 ~0 0 Left reticular thalamic nucleus* 
38,2,14 6.876 ~0 0 Right frontal operculum 
-32,-44,62 6.864 ~0 0 Left superior parietal lobule 
-52,-10,50 6.838 ~0 0 Left precentral gyrus 
-30,-40,44 6.828 ~0 0 Left postcentral gyrus 
-38,-4,52 6.823 ~0 0 Left middle frontal gyrus 
-54,-14,20 6.82 ~0 0 Left parietal operculum 
30,-4,48 6.812 ~0 0 Right middle frontal gyrus 
34,-2,48 6.786 ~0 0 Right middle frontal gyrus 
38,-2,50 6.773 ~0 0 Right middle frontal gyrus 
-30,-8,66 6.728 ~0 0 Left superior frontal gyrus lateral part 
-14,-78,40 6.706 ~0 0 Left parieto-occipital transition zone 
14,-22,64 6.642 ~0 0 Right precentral gyrus 
-32,-14,66 6.619 ~0 0 Left precentral gyrus 
30,-26,48 6.61 ~0 0 Right precentral gyrus 
-42,-28,58 6.593 ~0 0 Left postcentral gyrus 
-38,-32,56 6.591 ~0 0 Left postcentral gyrus 
-26,2,46 6.591 ~0 0 Left middle frontal gyrus 
36,-20,40 6.584 ~0 0 Right postcentral gyrus 
-10,-16,14 6.574 ~0 0 Left ventral lateral posterior thalamic 
-34,-34,62 6.567 ~0 0 Left postcentral gyrus 
46,-4,52 6.562 ~0 0 Right middle frontal gyrus 
24,-70,6 6.552 ~0 0 Right occiptal gyri 
-26,-32,54 6.534 ~0 0 Left postcentral gyrus 
-8,-26,12 6.517 ~0 0 Left medial dorsal thalamic nucleus 
-18,-74,40 6.505 ~0 0 Left parieto-occipital transition zone 
-12,-30,60 6.498 ~0 0 Left precentral gyrus 
-2,0,12 6.486 ~0 0 Left medial septal nucleus 
-14,-24,12 6.471 ~0 0 Left pulvinar 
-48,-24,48 6.447 ~0 0 Left postcentral gyrus 
6,-30,-18 6.435 ~0 0 Right cerebellum anterior lobe culmen** 
-54,-22,44 6.352 ~0 0 Left posterior central gyrus 
14,-14,40 6.332 ~0 0 Right posterior cingulate 
-10,-12,8 6.275 ~0 0 Left ventral anterior thalamic nucleus 
20,18,-8 6.187 ~0 0 Right posterior orbital gyrus 
-12,-34,66 6.181 ~0 0 Left postcentral gyrus 
2,-16,-2 6.179 ~0 0 Right ventral anterior thalamic nucleus** 
10,-40,-14 6.152 ~0 0 Right cerebellum anterior lobe culmen** 
-2,-18,52 6.133 ~0 0 Left paracentral lobule 
-24,4,66 6.114 ~0 0 Left superior frontal gyrus lateral part 
24,-74,22 6.098 ~0 0 Right precuneus 
-42,0,10 6.09 ~0 0 Left frontal operculum 
8,34,30 6.081 ~0 0 Right anterior cingulate 
-48,-20,56 6.067 ~0 0 Left postcentral gyrus 
-2,-30,-20 6.06 ~0 0 Left cerebellum anterior lobe culmen** 
14,-32,60 6.047 ~0 0 Right postcentral gyrus 
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-46,-34,40 6.039 ~0 0 Left supramarginal gyrus 
-26,-76,28 6.023 ~0 0 Left parieto-occipital transition zone 
-6,-34,-14 6.009 ~0 0 Left cerebellum anterior lobe culmen** 
44,-6,58 5.991 ~0 0 Right middle frontal gyrus 
12,-30,56 5.963 ~0 0 Right precentral gyrus 
14,-32,64 5.952 ~0 0 Right postcentral gyrus 
26,-6,58 5.948 ~0 0 Right superior frontal gyrus 
30,-54,38 5.948 ~0 0 Right superior parietal lobule 
-12,-20,0 5.921 ~0 0 Left paracentral lobule 
14,-44,-18 5.905 ~0 0 Right cerebellum anterior lobe culmen** 
-8,-32,54 5.889 ~0 0 Left precenral gyrus 
-48,-36,52 5.865 ~0 0 Left supramarginal gyrus 
-10,-36,52 5.85 ~0 0 Left paracentral lobule 
-40,-34,42 5.824 ~0 0 Left supramarginal gyrus 
-28,-6,4 5.809 ~0 0 Left putamen 
8,-20,10 5.807 ~0 0 Right medial dorsal thalamic 
38,-66,16 5.738 ~0 0 Right middle temporal gyrus 
-4,-26,64 5.711 ~0 0 Left paracentral lobule 
-34,4,4 5.709 ~0 0 Left claustrum 
6,14,26 5.699 ~0 0 Right anterior cingulate 
-16,-60,52 5.62 ~0 0 Left superior parietal lobule 
-60,2,12 5.615 ~0 0 Left precentral gyrus 
-18,-14,22 5.594 ~0 0 Left caudate 
28,-54,52 5.57 ~0 0 Right superior parietal lobule 
30,-76,26 5.566 ~0 0 Right angular gyrus 
-24,-56,48 5.543 ~0 0 Left superior parietal lobule 
48,-18,40 5.473 ~0 0 Right precentral gyrus 
-52,2,0 5.458 ~0 0 Left planum polare 
-18,-10,20 5.443 ~0 0 Left caudate 
54,12,32 5.423 ~0 0 Right inferior frontal gyrus  opercular part 
-18,-16,70 5.421 ~0 0 Left precentral gyrus 
-26,-54,42 5.42 ~0 0 Left superior parietal lobule 
-12,-30,72 5.389 ~0 0 Left postcentral gyrus 
36,26,8 5.347 ~0 0 Right inferior frontal gyrus orbital part 
12,-42,48 5.321 ~0 0 Right paracentral lobule 
56,8,38 5.312 ~0 0 Right inferior frontal gyrus opercular part 
8,22,26 5.299 ~0 0 Right subcallosal gyrus 
30,24,6 5.295 ~0 0 Right insular gyrus 
-52,-22,20 5.287 ~0 0 Left parietal operculum 
8,-48,-10 5.243 ~0 0 Right cerebellum anterior lobe culmen** 
0,-48,-18 5.229 ~0 0 Right posterior cingulate 
34,-74,14 5.218 ~0 0 Right middle temporal gyrus 
36,22,12 5.203 ~0 0 Right inferior frontal gyrus triangular part 
28,-50,44 5.196 ~0 0 Right superior parietal lobule 
58,8,14 5.178 ~0 0 Right precentral gyrus 
22,-64,42 5.148 ~0 0 Right superior parietal lobule 
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14,-30,46 5.118 ~0 0 Right paracentral lobule 
32,-76,10 5.094 ~0 0 Right occiptal gyri* 
22,-64,46 5.088 ~0 0 Right superior parietal lobule 
36,-74,10 5.088 ~0 0 Right middle temporal gyrus 
4,-54,-10 5.087 ~0 0 Right cerebellum anterior lobe culmen** 
16,-64,52 5.079 ~0 0 Right superior parietal lobule 
38,-28,46 5.073 ~0 0 Right postcentral gyrus 
-26,-66,52 5.059 ~0 0 Left superior parietal lobule 
26,-62,34 5.034 ~0 0 Right angular gyrus 
18,-66,34 5.014 ~0 0 Right precuneus 
-8,36,16 4.986 0.0011096 0.001370382  
-10,-10,-14 4.975 0.001140535 0.001402126  
38,-70,20 4.957 0.001186967 0.001439399  
18,-26,8 4.951 0.001186967 0.001439399  
18,-10,70 4.946 0.001217961 0.00146301  
22,-62,32 4.936 0.001228273 0.00146301  
-10,-70,46 4.93 0.001238585 0.001468765  
14,-32,40 4.913 0.001290202 0.001523234  
18,-60,4 4.911 0.001305699 0.001534769  
12,-64,54 4.907 0.001321197 0.001546204  
52,8,2 4.841 0.001491487 0.001730383  
12,-12,50 4.825 0.001579225 0.001808685  
18,-28,4 4.823 0.001605034 0.001830422  
52,0,16 4.814 0.001641154 0.001863683  
0,-22,-18 4.789 0.00174433 0.001964204  
-18,-88,18 4.774 0.001806259 0.00202278  
12,-78,12 4.733 0.001961112 0.002180822  
42,6,22 4.711 0.002038538 0.002257554  
14,-72,36 4.666 0.002275944 0.002499807  
40,10,22 4.657 0.002301693 0.00251777  
24,-60,28 4.649 0.002342999 0.002542201  
16,-58,48 4.643 0.002379119 0.002570983  
10,-74,38 4.628 0.002482355 0.002671772  
46,4,18 4.608 0.00258559 0.002744316  
18,-50,56 4.582 0.002750695 0.002857311  
6,-6,32 4.51 0.003210008 0.003308777  
16,-76,40 4.479 0.003478408 0.003517786  
48,6,26 4.457 0.003653884 0.003681357  
34,-46,56 4.387 0.004293799 0.004309881   
34,40,26 6.424 ~0 0 405 Right middle frontal gyrus 0.919 
40,54,6 5.306 ~0 0 Right middle frontal gyrus 
34,40,34 5.123 ~0 0 Right middle frontal gyrus 
32,54,12 4.945 0.001223087 0.00146301  
-34,42,28 6.679 ~0 0  
-32,38,20 5.437 ~0 0  
-34,52,14 4.829 0.001553416 0.001786762  
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-32,60,0 4.79 0.001739204 0.001964204  
-34,56,0 4.688 0.002172709 0.002396239  
-32,44,10 4.48 0.003452599 0.003504911   
-34,42,28 6.679 ~0 0 313 Left middle frontal gyrus 0.248 
-32,38,20 5.437 ~0 0 Left middle frontopolar gyrus 
-34,52,14 4.829 0.001553416 0.001786762  
-32,60,0 4.79 0.001739204 0.001964204  
-34,56,0 4.688 0.002172709 0.002396239  
-32,44,10 4.48 0.003452599 0.003504911   
-16,-22,38 6.322 ~0 0 124 Left paracentral lobule 0.097 
46,-52,-10 5.699 ~0 0 125 Right inferior temporal gyrus 0.139 
40,-56,-8 5.495 ~0 0 Right inferior temporal gyrus 
46,-46,-10 4.956 0.001186967 0.001439399   
-20,-72,10 5.476 ~0 0 83 Left occipital gyri 0.123 
-20,-70,4 4.604 0.002590716 0.002744316 
 
-40,-56,-6 5.440 ~0 0 51 Left inferior temporal gyrus 0.354 
-18,-42,-6 5.437 ~0 0 26 Left parahippocampal gyrus 0.910 
-6,-30,28 4.082 ~0 0 19 Left posterior cingulate 0.184 
-24,-56,8 3.967 ~0 0 18 Left striate 0.864 
-44,-42,-12 3.968 ~0 0 10 Left planum polare 0.740 
MNI (Montreal Neurological Institute), SDM-z (Signed Differential Mapping z-score), FDR (false discovery rate), *nearest grey matter 
















SDM-z P FDR Voxels Anatomical Description Egger’s 
test p 
-52,-64,36 -6.434 ~0 0 4857 Left angular gyrus 0.670 
-58,-58,28 -4.852 ~0 0 
-58,-62,22 -4.649 ~0 0 
-60,-18,-12 -3.097 ~0 0 
-56,0,-24 -2.751 ~0 0 
-58,-10,-14 -2.724 ~0 0 
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-62,-10,-20 -2.709 ~0 0 
-60,-32,-8 -2.506 0.000005186 7.64E-06 
-54,6,-30 -2.484 0.000005186 7.64E-06 
-60,-26,-10 -2.306 0.000005186 7.64E-06 
-68,-50,4 -1.105 0.000356078 0.000465507 
-60,-50,44 -0.7 0.001537919 0.001776562 
-60,-68,6 -0.461 0.003297746 0.003386191 
 
-44,36,-12 -4.623 ~0 0 5739 Left inferior frontal gyrus orbital part 0.074 
-40,16,48 -4.104 ~0 0 
-22,24,48 -3.667 ~0 0 
-56,24,14 -3.035 ~0 0 
-16,48,34 -3.031 ~0 0 
-12,30,54 -2.617 ~0 0 
-14,60,18 -2.424 0.000005186 7.64E-06 
20,26,48 -2.319 0.000005186 7.64E-06 
20,28,52 -2.262 0.000005186 7.64E-06 
-4,58,20 -2.231 0.000010312 1.51E-05 
-12,36,48 -1.922 0.000025809 3.72E-05 
-16,54,26 -1.789 0.000041306 5.89E-05 
-4,56,-8 -1.538 0.000092924 0.000131072 
18,42,46 -1.513 0.00009805 0.000136152 
16,46,42 -1.357 0.000165164 0.000225837 
36,24,48 -1.277 0.000221908 0.000298851 
12,54,34 -1.256 0.000237405 0.00031654 
10,56,26 -1.034 0.000474811 0.000611776 
-52,22,32 -0.647 0.001811445 0.00202278 
44,16,50 -0.336 0.004613757 0.004613757 
 
54,-62,30 -5.253 ~0 0 1736 Right superior temporal gyrus 0.613 
58,-58,30 -5.248 ~0 0 Right superior temporal gyrus 
42,-54,22 -2.989 ~0 0   
-8,-52,32 -3.102 ~0 0 2159 Left precuneus 0.756 
8,-52,32 -3.068 ~0 0 
0,-60,30 -2.934 ~0 0 
12,-52,12 -1.985 0.000025809 3.72E-05 
-10,-54,14 -1.923 0.000025809 3.72E-05 
 
62,-10,-20 -1.797 0.000041306 5.89E-05 807 Right middle temporal gyrus 0.570 
60,-4,-16 -1.77 0.000046432 6.58E-05 
54,-8,-28 -1.525 0.00009805 0.000136152 
48,6,-42 -1.497 0.00009805 0.000136152 
50,4,-28 -1.243 0.000247717 0.000327035 
48,0,-32 -1.088 0.000376761 0.000490155 
46,-12,-32 -0.873 0.000846386 0.00105503 
52,-8,-34 -0.867 0.000846386 0.00105503 
48,-16,-36 -0.757 0.001217961 0.00146301 
48,-8,-40 -0.548 0.002518475 0.002689049 




40,-12,12 -2.812 ~0 0 228 Right precentral gyrus 0.928 
26,-18,-24 -1.421 0.000139356 0.000192512 353 Right parahippocampal gyrus 0.750 
28,-10,-24 -1.347 0.00017029 0.000230494 
22,-6,-24 -1.261 0.000227094 0.000304306 
 
-24,-8,-24 -2.488 0.000005186 7.64E-06 213 Left parahippocampal gyrus 0.842 
18,-84,-48 -1.022 0.000521243 0.000662053 236 Right cerebellum posterior lobe inferior semi-
lunar lobule** 
0.297 
28,-82,-50 -1.007 0.000552177 0.000698035 
22,-84,-48 -0.981 0.000583172 0.000733756 
40,-70,-54 -0.573 0.002327502 0.002535653 
42,-66,-48 -0.526 0.002662957 0.002787783 
42,-62,-48 -0.456 0.003344178 0.003420762 
 
0,32,0 -1.185 0.000289023 0.000379697 90 Left anterior cingulate 0.608 
0,24,-8 -0.506 0.002859116 0.002958468 
 
0,-38,72 -1.35 0.00017029 0.000230494 63 Left paracentral lobule 0.252 
2,-48,70 -0.531 0.002642334 0.002787783 
6,-50,70 -0.527 0.002662957 0.002787783 
2,-60,64 -0.517 0.002750695 0.002857311 
 
-24,-40,8 -1.401 0.000149667 0.000205696 42 Left dentate gyrus 0.116 
-24,-42,4 -1.249 0.000242531 0.000321774 
-20,-38,12 -1.056 0.00043869 0.000567966 
-32,-46,0 -1.027 0.000495434 0.000635293 
-16,-36,12 -0.807 0.001057982 0.001312681 
 
32,6,-36 -1.022 0.000521243 0.000665625 36 Right fusiform gyrus* 0.039 
MNI (Montreal Neurological Institute), SDM-z (Signed Differential Mapping z-score), FDR (false discovery rate), *nearest grey matter 












Anticipation lose-vs-neutral activation maps only all peaks 
 
Peak MNI 
coordinate SDM-z P FDR Voxels Anatomical Description 
Egger’s 
test 
0,18,52 6.801 ~0 0 11315 Left superior frontal gyrus medial part 0.731 
2,-12,-2 6.254 ~0 0  Right posterior hypothalamic area   
32,-20,0 6.019 ~0 0  Right putamen   
-24,2,6 5.993 ~0 0  Left putamen   
6,-12,30 5.978 ~0 0  Right posterior cingulate   
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-58,2,28 5.801 ~0 0  Left precentral gyrus   
2,-28,-2 5.793 ~0 0  Right pretectal area   
-46,4,20 5.793 ~0 0  Left inferior frontal gyrus opercular part   
-52,6,44 5.75 ~0 0  Left precentral gyrus   
-48,12,18 5.739 ~0 0  Left inferior frontal gyrus opercular part   
-26,8,-2 5.672 ~0 0  Left prepiriform claustrum   
-14,-22,-2 5.666 ~0 0  
Left ventroposterior inferior thalamic 
nucleus   
-6,2,30 5.657 ~0 0  Left anterior cingulate   
12,-12,12 5.634 ~0 0  Right ventroanterior thalamic nucleus   
28,-6,8 5.61 ~0 0  Right putamen   
-22,8,-2 5.593 ~0 0  Left putamen   
26,-2,8 5.567 ~0 0  Right putamen   
32,14,8 5.554 ~0 0  Right insula   
-12,-20,2 5.518 ~0 0  Left ventrolateral posterior thalamic 
nucleus   
16,16,2 5.48 ~0 0  Right putamen   
40,30,2 5.474 ~0 0  Right inferior frontal gyrus triangular part   
52,12,34 5.444 ~0 0  Right inferior frontal gyrus opercular part   
-14,-18,12 5.429 ~0 0  Left ventrolateral posterior thalamic 
nucleus   
20,2,6 5.35 ~0 0  Right putamen   
26,2,8 5.338 ~0 0  Right putamen   
16,8,10 5.337 ~0 0  Right caudate   
6,12,56 5.327 ~0 0  Right superior frontal gyrus medial part   
30,0,12 5.325 ~0 0  Right claustrum   
-18,-28,8 5.187 ~0 0  Left lateral pulvinar   
2,28,48 5.181 ~0 0  Left superior frontal gyrus medial part   
12,-30,56 5.172 ~0 0  Right precentral gyrus   
-28,-10,60 5.167 ~0 0  Left superior frontal gyrus lateral part   
-4,8,56 5.161 ~0 0  Left superior frontal gyrus medial part   
-8,6,46 5.159 ~0 0  Left superior frontal gyrus medial part   
-4,2,62 5.157 ~0 0  Left superior frontal gyrus medial part   
38,30,8 5.126 ~0 0  Right inferior frontal gyrus triangular part   
-16,-6,-12 5.12 ~0 0  Left amygdala (basomedial nucleus)   
-18,-24,10 5.094 ~0 0  
Left ventroposterior lateral thalamic 
nucleus   
-6,18,22 5.082 ~0 0  Left anterior cingulate   
-4,6,62 5.08 ~0 0  Left superior frontal gyrus medial part   
-4,10,26 5.067 ~0 0  Left anterior cingulate   
-12,12,42 5.056 ~0 0  Left superior frontal gyrus medial part   
-50,0,14 5.052 ~0 0  Left precentral gyrus   
-4,6,44 5.05 ~0 0  Left anterior cingulate   
-22,-22,58 5.037 ~0 0  Left postcentral gyrus   
20,-26,10 5.036 ~0 0  
Right ventroposterior lateral thalamic 
nucleus   
8,-2,64 5.026 ~0 0  Right superior frontal gyrus lateral part   
-46,-2,48 5.014 ~0 0  Left middle frontal gyrus   
40,12,24 4.993 0.0001549 0.0003437     
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-10,14,0 4.986 0.0001549 0.0003437     
30,-12,8 4.979 0.00016 0.0003437     
-4,-24,64 4.975 0.00016 0.0003437     
-52,-36,36 4.968 0.00016 0.0003437     
-12,8,12 4.968 0.00016 0.0003437     
2,0,64 4.918 0.0001703 0.0003589     
26,18,0 4.916 0.0001755 0.0003607     
28,4,54 4.896 0.0001806 0.0003631     
44,16,8 4.889 0.0001806 0.0003631     
-14,10,0 4.886 0.0001806 0.0003631     
12,-16,38 4.868 0.000191 0.0003786     
-46,-8,54 4.86 0.0001961 0.0003864     
18,12,0 4.857 0.0002064 0.0003996     
-50,-8,50 4.852 0.0002064 0.0003996     
-30,-10,66 4.851 0.0002116 0.000405     
-12,4,0 4.84 0.0002271 0.0004296     
-12,6,4 4.837 0.0002271 0.0004296     
20,4,64 4.826 0.0002322 0.0004296     
8,-22,-8 4.802 0.000258 0.0004695     
44,18,2 4.802 0.000258 0.0004695     
4,44,34 4.796 0.0002632 0.0004764     
-20,-30,-2 4.795 0.0002683 0.000483     
-36,-4,56 4.79 0.0002838 0.0005054     
-2,-24,-12 4.783 0.0002993 0.0005199     
-34,-8,56 4.774 0.0003045 0.0005199     
60,10,18 4.75 0.0003406 0.0005735     
-36,-6,60 4.719 0.0003716 0.0006187     
-26,22,-2 4.703 0.0003819 0.0006297     
32,0,48 4.697 0.0003871 0.0006318     
6,30,32 4.689 0.0004026 0.0006508     
14,-26,0 4.682 0.0004077 0.0006559     
-4,-20,54 4.644 0.0004748 0.0007423     
10,26,24 4.644 0.0004748 0.0007423     
6,24,24 4.638 0.0004799 0.0007433     
-32,-10,46 4.627 0.0005006 0.0007659     
-40,2,32 4.625 0.0005006 0.0007659     
58,2,14 4.62 0.0005057 0.0007659     
-10,-30,68 4.605 0.0005109 0.0007699     
2,26,26 4.596 0.0005264 0.0007896     
-36,4,8 4.568 0.000578 0.0008517     
44,-4,50 4.56 0.0005832 0.0008517     
50,2,-6 4.559 0.0005832 0.0008517     
-28,28,-4 4.556 0.0005832 0.0008517     
44,10,14 4.505 0.0006812 0.0009736     
-4,-30,-18 4.472 0.000769 0.0010896     
-36,2,32 4.468 0.0007793 0.0010996     
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52,0,14 4.434 0.000867 0.0011833     
14,0,14 4.428 0.0008876 0.0012065     
14,-18,66 4.424 0.000898 0.0012156     
50,-2,42 4.415 0.0009134 0.0012265     
-36,24,12 4.414 0.0009134 0.0012265     
16,-4,16 4.412 0.0009186 0.0012285     
-56,-32,48 4.368 0.0010322 0.0013586     
64,4,12 4.357 0.0010683 0.0013951     
52,2,6 4.335 0.0011405 0.0014664     
-52,6,2 4.321 0.0011973 0.0015217     
-20,6,60 4.31 0.001218 0.0015305     
-32,24,12 4.3 0.0012799 0.0016023     
22,-4,54 4.298 0.001285 0.0016027     
-18,22,-2 4.29 0.001316 0.0016352     
52,14,2 4.274 0.0014089 0.0017312     
-34,8,28 4.271 0.0014296 0.00175     
50,4,0 4.251 0.0015121 0.0018377     
54,2,2 4.224 0.0016618 0.0019623     
8,0,2 4.202 0.0017443 0.002031     
38,6,12 4.193 0.0017753 0.0020581     
10,-12,-16 4.169 0.0018786 0.0021571     
2,-24,28 4.156 0.0019508 0.0022088     
-44,-40,56 4.151 0.0019714 0.0022088     
-30,28,6 4.15 0.0019714 0.0022088     
14,-4,-12 4.146 0.0019766 0.0022088     
42,2,-16 4.145 0.0019766 0.0022088     
12,-40,54 4.136 0.0020334 0.0022495     
40,0,8 4.121 0.0021263 0.0023445     
38,0,-6 4.118 0.0021417 0.0023538     
60,12,26 4.096 0.0022656 0.0024817     
-24,2,60 4.07 0.0024204 0.0026169     
-4,24,16 4.065 0.0024514 0.0026418     
-44,-20,60 3.998 0.0030758 0.0032209     
-36,-6,10 3.971 0.0033597 0.0034744     
-16,-12,60 3.954 0.0035197 0.0036174     
12,-32,42 3.94 0.0036642 0.0037201     
-50,-24,56 3.915 0.003948 0.0039599       
-28,-70,26 5.753 ~0 0 1854 Left parieto-occipital transition zone 0.359 
-24,-72,26 5.529 ~0 0  Left precuneus   
-16,-76,38 5.339 ~0 0  Left parieto-occipital transition zone   
-18,-72,40 5.306 ~0 0  Left parieto-occipital transition zone   
-18,-72,10 5.261 ~0 0  Left striate area   
-14,-72,10 5.162 ~0 0  Left striate area   
-18,-66,36 5.139 ~0 0  Left parieto-occipital transition zone   
-30,-46,38 5.129 ~0 0  Left superior parietal lobule   
-10,-72,14 5.123 ~0 0  Left striate area   
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-26,-50,44 5.101 ~0 0  Left superior parietal lobule   
-32,-48,44 5.023 ~0 0  Left supramarginal gyrus   
-28,-58,40 4.973 0.00016 0.0003437     
-36,-78,6 4.777 0.000304 0.0005199     
-24,-84,12 4.776 0.000304 0.0005199     
-16,-72,32 4.77 0.000304 0.0005199     
-22,-68,52 4.705 0.000382 0.0006297     
-36,-78,10 4.646 0.000459 0.0007249     
-26,-82,18 4.61 0.000506 0.0007659     
-10,-82,28 4.494 0.000702 0.000999     
-36,-86,14 4.435 0.000862 0.0011833     
-30,-78,-6 4.285 0.001352 0.0016675     
-30,-84,-2 4.231 0.001595 0.0019037     
-16,-94,12 4.226 0.001641 0.0019447     
-12,-96,8 4.04 0.00273 0.0028952     
-20,-58,50 4.019 0.002916 0.0030632     
-34,-38,48 3.945 0.003618 0.0036957     
-28,-84,6 3.944 0.003633 0.0036997     
              
30,-48,38 5.352 ~0 0 1491 Right supramarginal gyrus 0.185 
30,-54,38 5.207 ~0 0  Right superior parietal lobule   
34,-68,22 5.06 ~0 0  Right angular gyrus   
20,-68,42 5.016 ~0 0  Right angular gyrus   
22,-68,38 4.986 0.000155 0.0003437     
22,-80,26 4.984 0.000155 0.0003437     
22,-78,22 4.957 0.000165 0.0003522     
24,-68,2 4.882 0.000181 0.0003631     
24,-62,0 4.867 0.000191 0.0003786     
30,-80,14 4.777 0.000304 0.0005199     
26,-64,32 4.745 0.000356 0.0005957     
28,-72,26 4.668 0.000434 0.0006915     
20,-70,14 4.666 0.000434 0.0006915     
8,-66,10 4.562 0.000583 0.0008517     
22,-84,18 4.433 0.000867 0.0011833     
36,-50,52 4.37 0.001032 0.0013586     
12,-72,16 4.354 0.001079 0.0013981     
28,-60,-2 4.325 0.001192 0.0015208     
10,-78,12 4.316 0.001202 0.0015219     
34,-76,10 4.316 0.001208 0.0015237     
14,-64,4 4.232 0.001584 0.0018974     
38,-66,16 4.219 0.001677 0.0019733     
14,-90,20 4.172 0.001873 0.0021571     
28,-64,8 4.071 0.00242 0.0026169     
26,-64,24 4.05 0.002637 0.0028145     
38,-50,60 3.987 0.003169 0.0032875       
-30,-60,-10 6.286 ~0 0 461 Left hippocampus CA1 0.587 
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-42,-56,-10 5.687 ~0 0  Left inferior temporal gyrus   
-38,-58,-8 5.664 ~0 0  Left inferior temporal gyrus   
-42,-66,4 5.069 ~0 0  Left middle temporal gyrus   
-18,-44,-8 4.526 0.000645 0.0009338     
-18,-74,-6 4.517 0.000666 0.0009559       
52,-34,36 5.207 ~0 0 174 Right supramarginal gyrus 0.654 
24,-46,-8 5.28 ~0 0 88 Right fusiform gyrus 0.62 
36,42,26 4.457 0.0007948 0.0011074 83 Right middle frontal gyrus 0.184 
46,-56,-8 4.827 0.0002322 0.0004296 78 Right inferior temporal gyrus 0.143 
40,-58,-8 4.751 0.000341 0.0005735       
-36,36,32 5.056 ~0 0 70 Left middle frontal gyrus 0.757 
32,-20,66 4.829 0.0002322 0.0004296 57 Right precentral gyrus 0.67 
-12,-24,36 4.827 0.0002322 0.0004296 44 Left posterior cingulate 0.075 
-6,-26,40 4.147 0.001971 0.0022088       
-32,-24,14 4.524 0.0006606 0.0009523 41 Left insula 0.938 
-34,-20,-2 4.137 0.002028 0.0022495 
     
-36,-22,6 4.046 0.002678 0.0028491       
-36,-36,58 4.381 0.0010064 0.0013351 40 Left postcentral gyrus 0.285 
-50,-24,18 4.336 0.0011405 0.0014664 39 Left parietal operculum 0.754 
-54,-22,22 4.242 0.001553 0.0018736       
-14,-42,50 4.215 0.0016876 0.0019788 36 Left paracingulate 0.074 
-8,-40,52 4.189 0.00178 0.0020581       
56,-16,38 4.237 0.0015585 0.0018736 20 Right postcentral gyrus 0.407 
-26,48,-10 4.617 0.0005057 0.0007659 14 Left intermediate orbital gyrus 0.65 
4,-40,56 4.055 0.0025804 0.0027629 14 Right paracingulate 0.071 
8,-40,54 3.992 0.003259   Right paracingulate   
6,-44,54 3.963 0.0035599     Right paracingulate   
2,-48,-16 3.947 0.0035868 0.0036751 12 Right cerebellum anterior lobe culmen** 0.058 
MNI (Montreal Neurological Institute), SDM-z (Signed Differential Mapping z-score), FDR (false discovery rate), *nearest grey matter 











SDM-z P FDR Voxels Anatomical Description Egger’s 
test p 
8,64,16 -3.4 ~0 0 5037 Right superior frontopolar gyrus 0.435 
12,60,24 -2.838 ~0 0 
10,56,24 -2.79 ~0 0 
-4,62,18 -2.494 ~0 0 
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-2,34,0 -2.42 ~0 0 
-26,26,48 -2.389 ~0 0 
20,62,24 -2.381 ~0 0 
-8,60,8 -2.33 ~0 0 
2,54,-14 -2.266 ~0 0 
18,30,50 -2.235 ~0 0 
-12,60,24 -2.234 ~0 0 
-2,54,16 -2.206 ~0 0 
-36,16,44 -2.151 0.000005186 
1.56E-05 
-42,12,52 -2.12 0.000005186 
1.56E-05 
-14,38,44 -2.034 0.000030994 
9.22E-05 
-8,60,30 -2.024 0.00003612 
0.000105508 
-20,38,38 -1.973 0.000041306 
0.000117563 
16,40,42 -1.937 0.000051618 
0.000140892 
0,22,-8 -1.933 0.000051618 
0.000140892 
30,30,52 -1.912 0.000051618 
0.000140892 
-6,56,0 -1.863 0.000072241 
0.000182244 
-6,48,-4 -1.863 0.000072241 
0.000182244 
-16,50,30 -1.831 0.000072241 
0.000182244 
-8,42,-6 -1.825 0.000077426 
0.000192409 
-18,46,30 -1.775 0.00009805 
0.000240078 
38,24,52 -1.668 0.000159979 
0.000343742 
-16,54,30 -1.657 0.000159979 
0.000343742 
42,18,48 -1.611 0.000175476 
0.000360701 
-10,24,56 -1.581 0.000206411 
0.000399621 
-6,58,34 -1.299 0.000799954 
0.001109936 
-34,10,58 -1.225 0.001047671 
0.001373521 
-20,60,6 -1.121 0.001548231 
0.001873626 
-12,44,24 -1.105 0.001620471 
0.001927203 
30,18,60 -1.088 0.001728892 
0.002020074 
26,20,60 -1.047 0.001955926 
0.002208761 
-26,30,56 -0.984 0.002353311 
0.002569353 
-12,56,38 -0.977 0.002399802 
0.002611549 
-20,58,12 -0.932 0.002828121 
0.002989728 
 
-52,-66,32 -3.609 ~0 0 2191 Left superior temporal gyrus 0.199 
-54,-62,40 -3.588 ~0 0 
-36,-74,44 -3.146 ~0 0 
-42,-72,44 -3.082 ~0 0 
-34,-78,42 -2.919 ~0 0 
-48,-58,26 -2.778 ~0 0 
-38,-68,42 -2.739 ~0 0 
-62,-54,22 -1.982 0.000041306 
0.000117563 
-42,-84,24 -1.897 0.000061929 
0.000164979 
-62,-48,30 -1.304 0.000789583 
0.001107355 
 
-14,-52,32 -2.661 ~0 0 1974 Left precuneus 0.456 
-12,-48,28 -2.59 ~0 0 
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-6,-60,28 -2.569 ~0 0 
-4,-50,10 -2.353 ~0 0 
-12,-56,26 -2.343 ~0 0 
4,-60,30 -2.331 ~0 0 
2,-44,10 -1.795 0.000092924 0.000229213 
 
52,-68,34 -4.054 ~0 0 1609 Right angular gyrus 0.790 
58,-62,30 -3.977 ~0 0 
52,-64,30 -3.606 ~0 0 
60,-58,30 -3.57 ~0 0 
62,-56,16 -3.062 ~0 0 
64,-52,14 -3.011 ~0 0 
60,-60,12 -2.733 ~0 0 
68,-40,2 -2.003 0.00003612 
0.000105508 
66,-48,-2 -1.891 0.000061929 
0.000164979 
66,-44,4 -1.883 0.000061929 
0.000164979 
66,-32,0 -1.842 0.000072241 
0.000182244 
70,-30,0 -1.819 0.000077426 
0.000192409 
 
-60,-12,-16 -2.375 ~0 0 1105 Left middle temporal gyrus 0.333 
-64,-18,-18 -2.179 ~0 0 
-54,-10,-32 -2.133 0.000005186 
1.56E-05 
-54,-6,-26 -1.943 0.000051618 
0.000140892 
-48,12,-36 -1.377 0.000588357 
0.000855558 
-54,4,-32 -1.3 0.000794768 
0.001107355 
-64,-40,-8 -1.292 0.000820577 
0.001133826 
-60,-40,-8 -1.256 0.000970244 
0.001292365 
-48,6,-38 -1.162 0.001321197 
0.001635534 
-60,-6,-6 -1.049 0.001935303 
0.002208761 
-42,16,-40 -0.787 0.004417658 
0.004417658 
 
58,0,-18 -2.752 ~0 0 577 Right middle temporal gyrus 0.986 
66,-12,0 -1.872 0.000072241 0.000182244 
54,-6,-30 -1.759 0.000103235 0.000247318 
52,10,-32 -1.692 0.00013417 0.000312438 
54,12,-24 -1.618 0.000175476 0.000360701 
42,18,-40 -1.577 0.000211596 0.000404951 
44,0,-34 -1.569 0.000237405 0.000436773 
48,6,-42 -1.496 0.000340641 0.0005735 
50,4,-32 -1.424 0.000479937 0.000743344 
64,-4,-2 -1.038 0.002028227 0.002249523 
 
-44,38,-18 -2.156 0.000005186 1.56E-05 
 
413 Left inferior frontal gyrus orbital part* 0.862 
-54,24,8 -1.997 0.000041306 0.000117563 
-48,28,4 -1.951 0.000046432 0.000131033 
-40,32,-16 -1.692 0.00013417 0.000312438 
-48,30,-2 -1.668 0.000159979 0.000343742 
-48,34,-12 -1.548 0.000283837 0.000505442 




-16,-16,-26 -2.75 ~0 0 337 Left entorhinal cortex 0.862 
-22,-10,-22 -2.343 ~0 0 
-22,2,-24 -1.697 0.00013417 
0.000312438 
  
2,-58,66 -1.88 0.000072241 0.000182244 
 
302 Right paracingulate gyrus 0.006 
4,-62,64 -1.855 0.000072241 0.000182244 
4,-82,44 -1.766 0.000103235 0.000247318 
0,-76,52 -1.536 0.000294149 0.000519926 
2,-90,30 -1.528 0.000304461 0.000519926 
-2,-74,58 -1.457 0.00040257 0.000650756 
4,-88,34 -1.38 0.000577986 0.000851738 
-6,-68,64 -0.847 0.003684819 0.003729619 
 
20,-26,-26 -1.436 0.000459313 0.000724887 
 
124 Right cerebellum anterior lobe culmen** 0.929 
24,-20,-26 -1.215 0.001078606 0.001398082 
18,-18,-26 -1.2 0.001156032 0.00148061 
20,-20,-20 -0.953 0.002570093 0.002760777 
12,-12,-24 -0.928 0.002848744 0.003001999 
 
34,38,-12 -1.766 0.000103235 0.000247318 
 
96 Right lateral orbital gyrus 0.255 
42,38,-18 -1.648 0.00017029 
0.000358902 
  
-30,-32,-20 -1.601 0.000175476 0.000360701 
 
 
39 Left fusiform gyrus 0.903 
4,-28,74 -1.139 0.001434684 0.001749999 
 
14 Right precentral gyrus 0.026 
2,-38,74 -0.834 0.003818989 0.003853707 
-2,-40,72 -0.828 0.00389123 0.003914742 
 
56,28,18 -1.716 0.000123858 0.000294605 
 
 
12 Right inferior frontal gyrus opercular part * 0.201 
20,-36,12 -1.473 0.000387073 0.00063184 
 
10 Right stria terminalis 0.957 
MNI (Montreal Neurological Institute), SDM-z (Signed Differential Mapping z-score), FDR (false discovery rate), *nearest grey matter 






Supplementary Table 6: Between Group Linear Comparison anticipation win-vs-neutral minus 
anticipation lose-vs-neutral 
 
MNI coordinate SDM-z P FDR Voxels Description 
-6,38,18 2.923 0.003034532 0.004327869 8 Left anterior cingulate 
-44,38,-10 -2.776 0.000676095 0.004327869 36 Left inferior frontal gyrus orbital part 








Peak MNI coordinate SDM-z Voxels Anatomical Description 
-30,-92,-4 8.371 3305 Left occipital gyrus 
34,-88,-2 7.99 3090 Right occipital gyrus 
10,4,-6 7.171 1000 Right nucleus basalis 
30,20,-6 6.915 611 Right posterior orbital gyrus 
-38,20,0 6.439 192 Left inferior frontal gyrus orbital part 
-42,-22,54 5.703 150 Left postcentral gyrus 
-10,10,-6 5.784 95 Left nucleus accumbens 
-14,-10,66 5.793 87 Left superior frontal gyrus lateral part 
-4,-54,64 6.154 62 Left superior parietal lobule 
-30,-58,52 5.376 54 Left superior parietal lobule 
-54,6,12 5.658 38 Left inferior frontal gyrus opercular part 
50,4,34 5.295 38 Right precentral gyrus 
-52,8,-6 5.39 34 Left superior temporal gyrus 
-12,-72,-4 5.782 33 Left occipital gyrus 
-22,-24,-8 5.869 32 Left lateral geniculate nucleus 
32,-12,-6 5.992 24 Right limitans claustrum 
2,-66,0 5.726 23 Right cerebellum anterior lobe culmen 
-10,-16,42 5.334 17 Left posterior cingulate 
-10,-12,56 5.351 16 Left superior frontal gyrus lateral part 
2,-12,68 5.392 13 Right superior frontal gyrus lateral part 
-40,-64,24 5.295 13 Left angular gyrus 
60,8,22 5.295 13 Right precentral gyrus 
-50,-26,54 5.574 11 Left postcentral gyrus 
-60,-32,32 5.167 11 Left parietal operculum 







Peak MNI coordinate SDM-z Voxels Anatomical Description 
-42,-22,48 7.021 1171 Left postcentral gyrus 
-6,-8,50 6.745 593 Left paracentral lobule 
2,-52,-20 6.807 400 Right cerebellum anterior lobe culmen* 
10,6,2 6.221 192 Right fundus of the caudate 
38,-8,54 6.057 117 Right precentral gyrus* 
129 
 
-4,-24,-6 6.704 87 Left red nucleus 
-8,6,0 5.715 79 Left nucleus accumbens 
-24,-96,-8 5.654 37 Left occipital gyrus 
6,-48,36 5.544 35 Right posterior cingulat 
-18,-60,16 5.702 15 Left occipital gyrus 
32,24,2 5.295 14 Right inferior frontal gyrus opercular part 
56,-60,24 5.295 11 Right superior temporal gyrus 
0,40,-14 5.368 11 Left straight gyrus 
-8,-82,4 5.295 10 Left occipital gyrus 
MNI (Montreal Neurological Institute), SDM-z (Signed Differential Mapping z-score) 
 
 
Supplementary Figure 2: Binarised thresholded overlay map of heterogeneity and mean map 
activation and deactivation 
 
Top row anticipation win-vs-neutral; bottom anticipation lose-vs-neutral; heterogeneity is yellow, activation is red, deactivation is blue, 





Supplementary Figure 3: Binarised Jacknife density maps with mean maps of activation and 











Top row: mean map activation, bottom row Jacknife density map deactivation 






Top row- anticipation win-vs-neutral; bottom anticipation lose-vs-neutral; heterogeneity in yellow, activation red, deactivation blue, blue 
circles indicate visual overlap 
 
Supplementary Table 8: Meta-regression for Placebo Effect  
Anticipation win-vs-neutral 
 
Peak MNI coordinate SDM-z Voxels Anatomical description 
0,-60,-42 3.649 2614 Left cerebellum 
posterior lobe** 
-46,-72,40 2.738 28 Left angular gyrus 
28,24,48 2.322 22 Right middle frontal 
gyrus 
-16,2,-8 -4.112 991 Left substriatal terminal 
island (encompassing 
ventral striatum) 
24,0,-8 -3.421 212 Right putamen 
12,12,-12 -3.855 152 Right posteromedial 
orbital lobule 
-36,26,-12 -3.152 151 Left inferior frontal 
gyrus orbital part 
-8,-34,-18 -3.963 80 Left cerebellum anterior 
lobe** 
32,-84,30 -3.351 65 Right occipital gyrus 
-56,-2,12 -3.064 65 Left precentral gyrus 
46,12,-18 -3.091 30 Right middle temporal 
gyrus 
60,8,34 -3.200 15 Right inferior frontal 
gyrus opercular part* 
48,6,-30 -3.003 15 Right inferior temporal 
gyrus 
-44,-20,22 -2.882 15 Left frontal operculum 
-4,-4,28 -3.114 10 Left posterior cingulate 
gyrus 
MNI (Montreal Neurological Institute), SDM-z (Signed Differential Mapping z-score), *nearest grey matter structure, **Talairach client 
Anticipation lose-vs-neutral 
 
Peak MNI coordinate SDM-z Voxels Anatomical description 
132 
 
16,-64,-52 3.268 123 Right cerebellum 
posterior lobe* 
-22,36,46 3.125 109 Left superior frontal 
gyrus lateral part 
-6,-72,-40 3.341 57 Left cerebellum 
posterior lobe* 
-12,-58,-56 2.759 43 Left cerebellum 
posterior lobe* 
-36,-72,44 2.879 33 Left angular gyrus 
-14,60,12 2.943 30 Left middle frontopolar 
gyrus 
-8,56,28 2.912 13 Left superior frontal 
gyrus medial part 
-20,56,24 2.672 11 Left superior frontal 
gyrus lateral part 
-50,-60,42 2.667 10 Left supramarginal 
gyrus 
MNI (Montreal Neurological Institute), SDM-z (Signed Differential Mapping z-score), *Talairach client 
 
 




Top row: anticipation win-vs-neutral; bottom: anticipation lose-vs-neutral; heterogeneity in yellow, activation red, deactivation blue, blue 






Supplementary Table 9: Meta-regression for Field Strength 




Peak MNI coordinate SDM-z Voxels Anatomical description 
-56,-56,36 2.533 105 Left supramarginal 
gyrus 
-14,-46,38 2.837 101 Left posterior cingulate 
gyrus 
56,-58,34 2.424 93 Right superior temporal 
gyrus 
24,68,0 2.544 32 Right inferior 
frontopolar gyrus 
0,-30,14 2.55 20 Left thalamus 
-2,26,-12 2.126 19 Left straight gyrus 
-6,54,34 2.184 18 Left superior frontal 
gyrus, lateral part 
-48,-54,-12 -5.115 127 Left inferior temporal 
gyrus 
-22,-50,0 -4.309 56 Left lingual gyrus 
-22,-88,16 -4.485 34 Left occipital gyri 
-40,4,34 -3.747 30 Left precentral gyrus 
-20,-38,-28 -4.214 13 Left cerebellum anterior 
lobe culmen 
-6,-68,8 -3.511 12 Left striate area 
MNI (Montreal Neurological Institute), SDM-z (Signed Differential Mapping z-score) 
 
Anticipation lose-vs-anticipation neutral 
 
Peak MNI coordinate SDM-z Voxels Anatomical description 
-4,34,-14 4.495 2513 Left straight gyrus 
-4,-56,30 5.278 1405 Left posterior cingulate 
gyrus 
-52,-66,32 4.104 661 Left angular gyrus 
-66,-34,-6 3.917 616 Left middle temporal 
gyrus 
54,-64,28 5.038 507 Right superior temporal 
gyrus 
48,0,-32 3.305 297 Right inferior temporal 
gyrus 
-48,30,-10 3.515 256 Left inferior frontal 
gyrus, orbital part 
18,46,42 3.325 122 Right superior frontal 
gyrus, lateral part 
36,18,-32 2.709 85 Right inferior 
temporopolar region 
8,8,-16 2.544 56 Right anterior olfactory 
nucleus 
-30,-38,-16 3.241 52 Left fusiform gyrus 
-42,18,48 3.078 50 Left middle frontal gyrus 
34,26,-18 2.603 52 Right posterior orbital 
gyrus 
-18,-14,-24 2.983 30 Left entorhinal cortex 
24,26,58 2.514 30 Right superior frontal 
gyrus, lateral part 
50,26,-4 2.532 21 Right inferior frontal 
gyrus, triangular part 
-6,42,30 2.284 21 Left superior frontal 
gyrus, medial part 
50,-10,4 2.553 20 Right anterior transverse 
temporal gyrus 
-32,-14,-24 2.355 17 Left parahippocampal 
gyrus 




-18,30,44 2.427 14 Left superior frontal 
gyrus, lateral part 
-48,-32,52 -5.857 1642 Left supramarginal gyrus 
8,6,62 -5.31 613 Right superior frontal 
gyrus, medial part 
28,-50,46 -4.397 418 Right superior parietal 
lobule 
-52,4,14 -5.091 372 Right precentral gyrus 
28,-84,22 -5.509 344 Right parietal-occipital 
transition zone 
-38,44,22 -4.45 196 Left middle frontal gyrus 
-22,-90,18 -5.226 100 Left occipital gyri 
24,-60,6 -4.524 50 Right striate area 
-42,-2,50 -4.27 46 Left middle frontal gyrus 
38,36,34 -4.364 42 Right middle frontal 
gyrus 
60,8,14 -4.408 44 Right precentral gyrus 
-16,-18,72 -5.059 25 Left precentral gyrus 
8,-6,70 -4.806 19 Right superior frontal 
gyrus, lateral part 
34,0,54 -3.864 22 Right middle frontal 
gyrus 
-30,-76,24 -3.828 15 Left angular gyrus 
36,50,24 -3.725 15 Right middle frontal 
gyrus 
-62,-16,16 -3.506 14 Left reticular thalamic 
nucleus 
0,-50,-12 -3.42 13 Left cerebellum, anterior 
lobe culmen 
62,-40,36 -3.762 11 Right superior temporal 
gyrus 







































Table 1. Brain regions activated by the monetary incentive delay task in healthy controls 
 
Region Peak coordinate (MNI) Cluster size  p(FWE-corr) 
x y z 
Core salience network ROI analysis 
Right parietal operculum 
 
Left insula 














































Wholebrain analysis  






Left occipital gyrus (nearest GM) 
 
 
Right anterior cingulate 
Left occipital gyrus 
Left paracentral lobule 
Left cerebellum posterior lobe 
Right cerebellum posterior lobe 
 
 
Right lateral orbital gyrus 
Left paracentral lobule 
Left superior parietal lobule 
Right inferior frontal gyrus orbital part 
 
Right superior parietal lobule 
Right occipital gyrus 






























































































































Table 1. Brain regions activated by the monetary incentive delay task in healthy controls for motivational salience (salience>neutral) in 









Table 2. Wholebrain analysis for salience-vs-neutral contrast 
 
Region Peak coordinate 
(MNI) 
Cluster size p 
x y z 
Pairwise comparison 
CHR-PLB>HC 
Left superior frontal gyrus medial part -8 24 58 141 <0.001 
Left inferior frontal gyrus opercular part 
 
(Left frontal operculum) 
-54 20 20 65 0.002 
-44 16 12 0.004 
Left superior temporal 
gyrus/supramarginal gyrus 
-54 -54 30 13 0.009 
Pairwise comparison 
CHR-PLB>CHR-CBD 
Right superior frontal gyrus lateral part 20 -4 48 3 0.025 
Pairwise comparison 
CHR-CBD>CHR-PLB 
Right cerebellum posterior lobe 6 -82 -38 6 0.022 
3-way ANOVA  
CHR-PLB>CHR-CBD>HC 
Left superior frontal gyrus medial part -10 22 58 18 0.006 
Table 2. Wholebrain analysis for salience-vs-neutral contrast. Family wise error-corrected p<0.05, k≥3voxels. Abbreviations: HC=healthy 




































Figure 2. Whole-brain analysis of salience>neutral contrast (small-volume corrected, p<0.05 FWE-corrected at voxel level, k≥3 voxels). (A) 
Pairwise comparison CHR-PLB>HC with clusters in left superior frontal gyrus medial part, left inferior frontal gyrus opercular part extending 
to left frontal operculum and left superior temporal gyrus. (B) Pairwise comparison CHR-PLB>CHR-CBD with cluster in right superior frontal 
gyrus lateral part. (C) Pairwise comparison CHR-CBD>CHR-PLB with cluster in right cerebellum posterior lobe. (D) 3-way ANOVA CHR-
PLB>CHR-CBD>HC with cluster in left superior frontal gyrus medial part. (E) Mean b-value parameter estimates extracted from ANOVA-
derived cluster in the left superior frontal gyrus medial part for each group (CHR-PLB, CHR-CBD, and HC) showing increased activation in 
CHR-PLB relative to HC with CHR-CBD intermediate. (F) Positive correlation between mean b-value from ANOVA-derived cluster of left 

















In the exploratory whole-brain analysis, we report increased activation in the left SFGM, left IFGOP 
and left STG in HC-vs-CHR-PLB. In CHR-PLB-vs-CHR-CBD there was relative deactivation of the right 
SFGL and increased activation in the right cerebellum. A linear relationship was confirmed by ANOVA 
in the left SFGM, with CBD attenuating activation. This in turn correlated with reaction time during 
salience (r=0.377, p=0.011, CI=0.093-0.662; Supplementary Table 2, Supplementary Figure 2) absent 
in CHR-PLB and HC. CBD was associated with an overall slowing of motor response, suggesting a role 
modulating premature action. The pre-SMA region is thought to be critical to behavioural response 
selection and inhibition in measures of response inhibition (Simmonds, Pekar et al. 2008). 
 
 
